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Abstract:  
 
Distal sensorimotor peripheral neuropathy (DSPN), the classical length dependent 
symmetrical neuropathy of diabetes, can affect up to  50% of those with diabetes 
leading to significant morbidity, mortality and healthcare costs. There is 
increasing recognition that small nerve fibres, mediating pain, temperature and 
autonomic function, are involved early in the course of diabetic neuropathy, 
preceding large fibre involvement. However, assessment small fibre neuropathy 
(SFN), continues to be a significant challenge. The currently available options are 
either invasive, subjective with poor reproducibility, may not directly assess the 
region of interest or are still in a research phase. Thus, there is an ongoing need 
for  simple, non-invasive and reproducible techniques for the evaluation of SFN.  
The laser Doppler imager flare (LDIflare)  is one such novel, non-invasive 
technique of assessing small fibre function. It has been shown to be a reliable 
indicator of small fibre neuropathy, even when other  SFN markers are either 
inconclusive or normal. However, the original methodology, took over an hour to 
complete, which limited its use as a clinical tool. The LDIflare methodology was 
therefore modified to overcome this limitation by incorporating an accelerated 
acclimatisation phase and a shorter duration of skin heating but at a higher final 
temperature reducing the total procedure time to under 30 minutes. The size of the 
resultant flares was nearly twice as large compared to the older method while 
demonstrating similar group differences in those with and without clinical 
neuropathy. Assessment of the LDIflare in  healthy volunteers (n=94) 
demonstrated significant inverse relationship of LDIflare size to age (r=-0.42, 
p<0.0001) but not with other anthropometric or metabolic factors except for 
fasting triglycerides (r=-0.36, p<0.0001). Furthermore, the LDIflare possessed a 
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sensitivity of 77%, specificity of 90%, positive predictive value (PPV) of 82% and 
negative predictive value of (NPV) 87% for the detection of clinical neuropathy. 
Recent observations, exploring into the aetiopathogenesis of diabetic neuropathy, 
have suggested that triggers for neuropathy development in the two main forms of 
diabetes may be different. Small fibre function (SFF) in individuals with type 1 
diabetes with (MV+, n=24) and without (MV-, n=24) renal and retinal 
microvascular disease, but all without clinical neuropathy was assessed using the 
LDIflare. The finding of abnormal SFF  only in the MV- group suggests that 
direct microvascular damage is an early aetiopathogenic factor in type 1 diabetes. 
Furthermore, in another study of normal glucose tolerant individuals not meeting 
the criteria for metabolic syndrome, SFF was observed to be abnormal with 
increasing fasting triglyceride concentrations. This is suggestive that 
hypertriglyceridaemia may play a pathogenic role in the development of neural 
dysfunction, and may partly explain the presence of neuropathy early in the 
course of  type 2 diabetes, when significant hyperglycaemia is not a factor. 
The LDIflare in its current modification is a novel, reliable, non-invasive measure 
and objective method of detecting small fibre neuropathy. It has good 
reproducibility and offers excellent accuracy for the detection of clinical 
neuropathy. The age based normative values allow for a clear distinction of 
abnormal results. While further comparative studies between the LDIflare and 
modern markers of SFN are desired, the studies included in this submission 
support the use of the LDIflare technique to investigate abnormalities in the 
peripheral nervous system, in particular small nerve fibres, in research but also in 
clinical domains.  
13 
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1.0 Introduction 
 
Diabetes Mellitus is a complex metabolic disorder characterised by defects in 
insulin action, insulin secretion or both, resulting in disturbances of carbohydrate, 
fat and protein metabolism [1].  The burden of diabetes has been rapidly 
increasing, affecting up to 347 million individuals worldwide, with prevalence 
rates reaching 9.8% in men and 9.3% in women [2] . In addition, a significant 
number live with the condition undiagnosed and it is projected that with an aging 
population and  the continued rise in obesity, the global prevalence of diabetes 
will reach 530 million individuals by the year 2035. At the same time, an 
increasing number of individuals are being diagnosed with prediabetes, a 
biochemical state where the glycaemic variables that are higher than normal, but 
lower than the thresholds for diabetes, many of whom will eventually develop 
diabetes [3]. The prevalence of prediabetes is projected to reach 470 million by 
year 2030, a number not dissimilar to projected diabetes figures for same time 
period [3-4].  Given the enormity of the numbers affected, diabetes is perceived as 
a major public health challenge with substantial healthcare costs associated with 
managing the condition and its complications [5-6]. A recent study from the 
United Kingdom (UK) put the total cost of managing diabetes in the year 
2010/2011 at around £24 billion while estimating that by the year 2036/2037, 
these costs will rise to nearly £40 billion [5]. Figures emerging from other 
countries also demonstrate a similar or higher degree of economic burden and the 
overall picture is one of high cost with continued individual and societal suffering 
[6-7].  
The chronic complications accompanying diabetes can be divided into 
macrovascular – those affecting the larger blood vessels such as myocardial 
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infarction, stroke or peripheral vascular disease and, microvascular – those 
affecting the small blood vessels, leading to the development of neuropathy, 
nephropathy and retinopathy. Neuropathy is perhaps the most common 
microvascular complication, ultimately affecting more than 50% of those with 
diabetes [8]. Diabetic Neuropathy (DN) is a collective term for a heterogeneous 
group of conditions that affect different parts of the nervous system and present 
with diverse clinical manifestations [9]. Although any part of the nervous system 
can be affected, the most common presentation is the length dependent distal 
sensory predominant sensorimotor neuropathy (DSPN) which accounts for over 
80% of the cases.  
The consequences of DN are significant – it can lead to considerable morbidity 
[10] and is increasingly recognised to confer an increased mortality risk [11-12]. 
Development of DSPN in particular, may lead to neuropathic pain, foot 
deformities, loss of protective pain sensation and foot ulceration. In the latter 
group, development of infection may increase the risk of a future lower extremity 
amputation [13].  The life expectancy of patients with neuropathic foot ulceration 
is approximately 50% at 5 years, an outcome worse than many of the major 
cancers including breast, colon and prostate [14]. Like diabetes in general, the 
healthcare costs associated with DN and its associated complications are 
significant. In the year 2003, it was estimated that the direct cost of managing 
DSPN in the UK was £252 million[15], but a more recent estimate for the year 
2010/2011, commissioned by the charity Diabetes UK, which included the cost of 
all diabetes related neurological conditions and  foot disease, has put the figure 
closer to £1.2 billion [6]. At the moment, there are no pathogenesis-based 
treatments available for diabetic neuropathy, apart from good glycaemic control. 
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Although many putative agents with disease modifying potential have been 
investigated, none are currently licensed for the treatment of DN/DSPN [16]. 
Therefore, early recognition is vital. Findings from the Diabetes Control and 
Complications Trial/Epidemiology of Diabetes Interventions and Complications 
(DCCT/EDIC) studies have demonstrated that the clinical course of diabetic 
complications in type 1 diabetes, DSPN in particular, may be influenced by 
improved glycaemic control [17].  It is thought that the development of DSPN has 
a temporal trend resulting in a clinical spectrum ranging from early, almost 
undetectable, asymptomatic changes to an advanced stage with loss of protective 
sensation [18-20]. The early neuropathic changes by virtue of being asymptomatic 
are unlikely to be recognised by patients and clinicians alike. Unlike retinal 
imaging for diabetic retinopathy and microalbuminuria for nephropathy, no 
simple marker indicative of early neural damage exists for DSPN. Commonly 
used  neuropathy screening devices such as the 10gm monofilament or the 128Hz 
tuning fork only detect advanced neuropathy and lack sensitivity for early 
neuropathy [21].  It has been suggested by experts that more advanced neuropathy 
is less likely to be amenable to therapy [16, 22]. Recognising neuropathy earlier 
may thus increase the 'window of opportunity' - allowing for intensification of 
diabetes therapy, management of associated vascular risk factors and for 
institution of interventions aimed at arresting the progression to more advanced 
neuropathy. Therefore, research aimed at recognition of early diabetic neuropathy 
and amelioration of its progression is considered an urgent clinical need.  
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2.0 Small Fibre Neuropathy in Diabetic Neuropathy : Significance and 
Emerging focus 
 
2.1 The nerve fibres 
 
The Nobel laureates Gasser and his mentor Erlanger in studies of mammalian 
neural tissue, observed neurologic structural deficits by cautious sectioning of 
nerve fibres and subsequently classified nerve fibres into A, B and C groups. 
Subtypes of the A-fibres -  A -alpha (afferent or efferent fibres), A -beta  (afferent 
or efferent fibres), A -gamma (efferent fibres) along with B- fibres are considered 
as large fibres on account of their generous myelination. These are fast conducting 
and mediate sensory modalities such as proprioception, touch, pressure and 
vibration alongside mediating afferent and efferent motor function. Small nerve 
fibres are slow conducting and comprise of the thinly myelinated A -delta and the 
non-myelinated C-fibres (Table 1). Overall, the small fibres make up between 
55% - 70%  of the peripheral nerves; the A-delta fibres constitute ∼80% of 
primary sensory nerves sprouting from dorsal root ganglia, whereas the C -fibres 
make up ∼20% of the primary afferents [23].  Together, these nerve fibres 
mediate pain, temperature perception and autonomic function. Thus, small fibre 
neuropathy (SFN)  may  lead to generation of nociceptive pain (neuropathic pain),  
abnormalities of temperature perception, impairment of vasodilatory responses 
and also impaired  sweating, heart rate variability, abnormal blood pressure 
response to stimuli  and symptoms of visceral dysautonomia.   
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Table 1. Classification of Nerve Fibres  
m/s= metres/second  
Type Size Conduction Innervation Myelination 
Large Nerve fibres 
 
A-alpha  13-20 
micrometers 
70-120 m/s Muscular spindles and tendon 
organs , Limb proprioception 
 
Yes 
A-beta  6-12 
micrometers 
35-75  
m/s 
Limb proprioception, 
vibration, pressure, capture 
touch receptors 
 
Yes 
A-gamma 4-8 
micrometers 
15-40 m/s touch, pressure, motor 
neurons to muscle spindles 
 
 Yes 
Small nerve fibres 
 
A-delta  1-5 
micrometers 
4-30  
m/s 
Mechanical sharp pain 
Cold sensation 
 
Yes, thinly 
C-Fibres 0.2-1.5 
micrometers 
0.5-2  
m/s 
Warm sensation , Thermal 
pain, mechanical/ burning 
pain 
Autonomic fibres 
No 
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2.2 Diabetic Neuropathy and Small Nerve Fibres 
 
There is increasing recognition that small nerve fibres are involved early in the 
course of neuropathy development in both forms of diabetes [24-27] and also in 
prediabetic states [28-29] . Although the precise sequence of nerve fibre damage 
remains unclear, mainly because of the lack of longitudinal studies, assessment of 
small fibre parameters in crossectional cohorts has suggested that  small fibre 
change may precede large fibre involvement [27, 30-32]; however these findings 
are not consistent [18].  Therefore, small fibre neuropathy (SFN) assessment 
techniques have an important role in  not only in characterising the presence of 
diabetic neuropathy but also in the recognition of early diabetic neuropathy. 
In addition to the potential role in the diagnosis of early diabetic neuropathy, 
understanding small fibre neuropathy may be important in unravelling the 
aetiopathogenesis of diabetic neuropathy. There is emerging evidence that the 
pathogenesis of neuropathy differs between type 1 and type 2 diabetes. 
Ultrastructural studies have suggested that paranodal degeneration seen in 
neuropathy of type 1 diabetes is not seen in type 2 diabetes, with axonal loss and 
atrophy expressed to a larger extent in the former [33]. While improvement in 
glycaemic control has shown to significantly reduce the risk of diabetic 
neuropathy in type 1 diabetes [17, 34], there is only a modest improvement in 
neuropathy risk reduction in type 2 diabetes [9, 34]. Therefore, factors in addition 
to hyperglycaemia are thought to potentially contribute diabetic neuropathy, 
especially in type 2 diabetes, and may also be responsible for driving the earliest 
damage. This is supported by a growing body of literature linking prediabetes and 
neuropathy, which is typically of the small fibre type [35].  The metabolic, 
immunologic an clinical correlates of SFN may provide with insights into how 
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neuropathy develops and may also in time allow for the development of 
interventions designed to alter the course of neuropathy.  
At the same time, it is felt by experts that small fibre assessments may be better 
suited as future surrogate endpoints in neuropathy clinical trials than the current 
large fibre based measures [9, 22]. Longitudinal follow up of diabetic subjects has 
suggested the progression of large fibre neuropathy is minimal during a 1-5 year 
follow up period, typical of most studies, but that the progression of small fibres 
may be more rapid [36-38]. However, at what stage such a progression in a 
particular small fibre marker constitutes a meaningful, clinically relevant change 
is also unclear. This particular area needs attention as until this occurs, their 
relevance as true 'clinical endpoints' for research will remain challenged. 
Despite significant research and many molecules with putative disease 
modification potential entering into phase III trials, there are currently no licensed 
treatments for diabetic neuropathy. The most significant reason for failure in 
clinical trials has been the lack of demonstrable treatment efficacy. While the 
reasons for this have been greatly debated including poor subject selection, short 
duration on intervention, and lack of homogeneity between study groups [16, 22, 
39-40], a recent line of enquiry has been questioning the appropriateness of  study 
endpoints recommended by regulatory authorities, which are predominantly 
clinical and large fibre based by which time the neuropathy may not be reversible 
[41-42] . It has been advocated by some that small fibre based endpoints may be 
superior, as these fibres are damaged early, and may be therefore, potentially more 
amenable to regenerative or corrective therapy [22, 43].  However, there is no 
current consensus on which of the small fibre techniques are best suited. As a 
consequence of the above factors, a significant clinical and research focus is 
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emerging into the understanding of small fibre neuropathy and into its detection 
techniques.  
2.3 Diagnostic Criteria for  Small Fibre Neuropathy 
 
The diagnostic criteria of SFN in diabetes mellitus were reviewed by the Toronto 
Consensus on Diabetic Neuropathy panel, who proposed a grading of SFN into : i) 
Possible SFN  - length dependent symptoms and/or clinical signs  ii)  Probable 
SFN  - symptoms and signs as above and normal sural nerve electrophysiology, 
iii)   Definite SFN  - symptoms and signs as above, normal sural nerve 
electrophysiology and altered intra-epidermal nerve fibre density at the ankle 
and/or abnormal quantitative sensory testing of thermal thresholds at the foot [31]. 
'Subclinical SFN' was considered if there were abnormalities on a validated SFN 
marker but no symptoms and signs.  
2.4 Techniques for  Small Nerve Fibre Assessment 
 
Detection of small fibre neuropathy, however, continues to be a significant 
challenge. DSPN in particular, is typically suspected when symptoms such as 
numbness, burning/throbbing pain, hyperaesthesia, hyperalgesia or parasthaesia  
are reported. However, early diabetic neuropathy can be asymptomatic and typical 
symptoms are often not recognised until the abnormalities are well advanced.  
Clinical examination for reflexes, proprioception, light touch, vibratory perception 
and motor strength is normal in pure SFN. Therefore in the absence of clinical 
signs and symptoms to guide the diagnosis, there is a need for precise and reliable 
testing methodologies for detecting and confirming SFN.  Nerve conduction 
studies are widely used to assess and quantitate nerve function but they detect 
only large fibre function, and are therefore, not suitable for the initial assessment 
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of SFN. Their role in SFN is complementary - to detect or exclude any associated 
large fibre component [31, 44]. Recognising the importance of detecting such 
early neuropathy, the Toronto Diabetic Neuropathy Consensus document has 
recommended  the use of small fibre testing, using a validated marker, when nerve 
conduction assessment is normal [31].  
Until recently, most diabetic neuropathy guidelines and position statements paid 
limited  cognizance to the importance of small fibre neuropathy. This was 
primarily because most small fibre techniques were still in a research phase with 
limited clinical utility. The 2017 position statement on diabetic neuropathy by the 
American Diabetes Association has recently recommended using pinprick and 
temperature sensation as bedside screening tests for small fibre function [9]. 
However, over the last three decades, significant progress has been made in the 
development of techniques which allow for more detailed, clinically valuable, 
small fibre characterisation and measurement [45]. They are divided into two 
main groups:  
I) Structural methods - allowing for morphometric analysis or quantitative 
measurement of the small nerves. Examples include skin biopsy and in-vivo 
corneal confocal microscopy (IVCCM). 
and 
 II) Functional markers - these assess function of the small fibres, mainly 
indirectly. Many functional techniques are qualitative but quantitative 
methodologies are available and beginning to be more widely utilised. Examples 
include quantitative sensory testing (QST) for thermal and pain thresholds, 
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contact heat evoked potentials, sudomotor assessment techniques and the laser 
Doppler imager flare (LDIflare) [45].  
Table 2  summarises the characteristics, principles and limitations of some of the 
main small fibre assessment tools. 
2.4.1 The case for newer small fibre techniques 
 
Skin biopsy with measurement of the intra-epidermal nerve fibre density (IENFD) 
has been recently proposed as a 'gold standard' technique for the assessment of 
SFN [46-47]. It allows for precise structural quantification and has well 
established worldwide normative data [48]. However, its invasive nature is a 
limitation, especially for application in large longitudinal studies requiring 
repetitive assessments. Quantitative sensory testing (QST) of temperature and 
pain thresholds  is a non-invasive technique widely used in clinical practice as 
well as research studies [46, 49-51]. Well recognised limitations include the 
subjective, psychophysical nature of testing and its inability to distinguish 
between a peripheral and a central lesion. Additionally and specifically in 
relevance to diabetic neuropathy,  it has been shown that there is poor relationship 
between quantitative sensory tests and morphometric indicators of small nerve 
fibre damage and repair [52]. In-vivo corneal confocal microscopy (IVCCM) with 
visualisation small nerve fibres in the subbasal nerve layer of the Bowman layer 
of the cornea has received significant recent attention [53-54].  It is easy to 
acquire the images, non-invasive, has been validated against IENFD [55-56] and 
possesses good sensitivity and specificity for the detection of DSPN [56-57] . In 
addition, multi-centre reference values have been recently established [58]. A 
major limitation is that IVCCM detects changes that could be considered 'far 
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away' from the distal leg. Moreover, morphometric analysis of the corneal 
epithelial nerve terminals is not possible and variation in data has been reported, 
especially in cloudy and fibrotic corneas [59]. Furthermore, it is unclear which 
among the three parameters measured using IVCCM are best suited for 
neuropathy assessment. While other SFN techniques are available and 
summarised in Table 2, many are still in a research validation phase with limited 
clinical experience.  
Another challenge for SFN techniques is their  ability to detect meaningful 
improvement with treatment. Although IENFD has been shown to improve in 
subjects receiving intensive lifestyle treatment for impaired glucose tolerance [60] 
and IVCCM has shown improvement in treated type 2 diabetes [61] and after 
pancreatic transplantation [62-63],  the cohorts studied were small or the within 
group changes not significant.  Thus, there is an overall  need for newer SFN 
measures that are simple, non-invasive, reliable and with an ability to detect a 
response to treatment. 
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Table 2. Overview of the main tests used in small fibre assessment currently.  
 
Tests for Small fibre Neuropathy 
Structural tests for SFN  
Test Type Technique Equipment 
Needed 
Time to acquire 
results 
Normative Data Operating 
Characteristics for 
DSPN 
Limitations 
Skin Biopsy Invasive 
(minimally), 
quantitative 
Measurement 
of intra-
epidermal 
nerve fibre 
density 
Sterile equipment 
for biopsy, access 
to trained 
personnel and 
laboratory 
 Procedure takes 5-
10 minutes  but 
takes a few days to 
get the results 
back. 
Worldwide 
normative Data 
present 
Published 
sensitivity to detect 
DSPN is between 
60% and 95% and 
specificity between 
90% and 95% 
Challenging to use in 
prospective studies of very 
large cohorts, infection risk 
at site of biopsy 
Needs operator training and 
access to high quality 
pathology services 
Sural nerve 
biopsy 
Invasive, 
quantitative 
Ultrastructure 
and 
morphometric 
analysis of 
sural nerve 
biopsy 
specimens 
Experienced 
operator who can 
perform biopsy and 
access to 
pathologist and at 
times, electron or 
confocal 
microscope 
Procedure may 
take up to 45 
minutes. Results 
usually take a few 
days. 
None available None available Infection, pain and 
hypoesthesia at biopsy site 
Corneal 
Confocal 
Microscopy 
Non-invasive, 
quantitative 
Measurement 
of nerve 
parameters of 
the corneal sub-
basal layer 
Corneal scanning 
confocal 
microscope, 
trained technician 
Image acquisition 
takes 5-10 minutes. 
Results available 
immediately if 
automated 
counting  used 
Worldwide 
normative Data 
present 
Reported sensitivity 
of 85% and 
specificity of 84% 
Surrogate marker of  DSPN 
rather than a direct indicator. 
Previously reliant on manual 
counting but newer 
automated methods 
emerging. Unclear which of 
the three- CNFB, CNFL or 
CBNFD best 
representative/predictive of 
DSPN 
Cost of equipment is 
significant 
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Functional tests for SFN  
 
Quantitative 
sensory testing 
(QST) 
Non-invasive, 
quantitative 
Computerised 
measurement of 
thermal 
thresholds and 
heat pain 
thresholds 
Computerised 
assessment device, 
temperature 
controlled 
laboratory and a 
trained technician 
Takes about half 
an hour but could 
take longer, 
depending on 
subject 
concentration 
Commercial 
normative data 
present from the 
bigger 
manufacturers.  
 Psychophysical test- results 
are dependent on subject 
compliance and attention. 
Complex testing protocols 
present . Varying 
reproducibility depending on 
experience of the unit 
undertaking testing.  
 Laser Doppler 
imager Flare 
(LDIflare) 
Non-invasive, 
quantitative 
Measurement 
of the axon-
reflex mediated 
flare response 
as a marker of 
small fibre 
function 
Laser Doppler 
imager, 
temperature 
controlled room, 
operator with 
experience 
Image acquisition 
took ~1 hour with 
the older method. 
Newer method 
takes 
approximately 25 
minutes (discussed 
within the thesis). 
Results available 
immediately 
One site 
normative values 
determined at a 
single centre. 
Larger data set of 
normative valves 
desired 
For the newer 
technique: 
Sensitivity of 70-
75%, specificity of 
66-85% , positive 
predictive value of 
74%, and negative 
predictive value of 
86% 
Dependent on the 
microcirculation. Patients 
need to have no significant 
macrovascular distal 
circulatory impairment.  
Current 
perception 
threshold 
(CPT) 
Non-invasive, 
quantitative 
Low current 
intensity 
stimulation of 
the small nerve 
fibres at 
frequency of  
250 Hz for A-
delta fibres and 
the 
5 Hz for C-
fibres. 
Neurometer device 
temperature 
controlled room 
and a trained 
technician 
Takes about half 
an hour but could 
take longer, 
depending on 
subject 
concentration 
None available. 
Most studies 
have included age 
matched controls 
for comparison.  
None available Requires active patient co-
operation. Like QST, 
therefore reproducibility has 
been a challenge and other 
methodological challenges 
persist (such as what 
frequency to use. Not widely 
available.  
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Contact Heat 
Evoked 
Potentials 
(CHEPs) 
Non-invasive, 
quantitative 
Measure 
cerebral 
responses to 
thermal stimuli 
mediated by A-
delta fibres 
Needs thermal 
threshold testing 
first. Then small 
discs are placed on 
the head to record 
signals received to 
the brain from 
application of 10 to 
20 short (a fraction 
of a second) heat 
or cold 
stimuli at a 
particular point of 
interest (face, arm 
or leg) 
Takes about half 
an hour but could 
take longer, 
depending on 
subject 
concentration 
Multicentre 
normative data on 
226 adult 
subjects are 
available 
The AUC for DSPN 
detection  in a small 
sample has been 
estimated at 0.778. 
Requires active patient co-
operation. Like QST and 
CPT, therefore 
reproducibility has been a 
challenge. Not widely 
available. Also unclear if 
both A-delta and C-fibres 
are assessed.  
Participant discomfort is 
another major limitation of 
use.  
Microneuro-
graphy  
Minimally  
invasive, semi 
quantitative 
Measurement 
of Single fibre 
recordings from 
peripheral 
axons  
Skilled operator 
and extensive 
equipment list. 
Preserve of a large 
neurophysiology 
lab rather than 
clinic based 
procedure. 
May take up to 3 
hours to get a 
satisfactory 
recording.  
None available None available. 
Considered by 
EFNS to possess 
grade A evidence 
for assessing 
function of the A-
delta fibre pathways 
in patients with 
neuropathic pain  
Still primarily a research 
tool. May have a role in 
assessment of neuropathic 
pain rather than early 
neuropathy. Expensive and 
needs skill to elicit 
responses.  Patient 
cooperation is also 
extensively required. 
Laser Evoked 
Potentials 
(LEPs) 
Non-invasive, 
quantitative 
Radiant heat 
generate by 
laser selectively 
excites free 
nerve 
endings in the 
superficial skin 
layers 
activating 
nearby A-delta 
and C -fibre 
nociceptors  
CO2-laser 
stimulator, 
technician with 
experience and a 
temperature 
controlled room 
ideally. 
May take up to 1 
hour to complete 
the procedure and 
ensure no artefacts 
presents in 
readings gained 
Single centre 
normative values 
available on 100  
subjects. No 
decade specific 
data reported. 
None available. 
Studies have used 
age matched control 
data. 
Limited availability.  May 
be useful in demonstrating 
reduced function but unable 
to detect enhanced 
transmission as found in 
hyperalgesia. Small changes 
in pain sensitivity are not 
easily detectable with LEP  
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Quantitative 
sudomotor 
axon reflex test 
(QSART) 
Sudomotor 
Non-invasive, 
quantitative 
Information on 
skin autonomic 
function  and 
evaluation of 
postganglionic 
sudomotor 
function using 
acetylcholine 
iontophoresis  
Purpose built 
lab, 
iontophoresis  
and sudomotor 
quantification 
equipment. 
45-60 minutes to 
complete. 
Normative data 
available from 
specific centres 
for QSART. A 
commercially 
available device 
QSWEAT is also 
available 
No specific data 
available for DSPN 
but has been widely 
used, especially in 
the Rochester 
Diabetic 
Neuropathy study 
Requires precautions for 
electrical safety and small  
risk of minor local injury to 
the skin 
Thermo-
regulatory 
sweat test 
(TST) 
Sudomotor 
Non-invasive, 
semi-
quantitative 
When core 
temperature 
rises beyond a 
hypothalamic 
thermoregulatory 
set point (>38°C), 
sweating occurs 
Needs a 
laboratory and a 
digital camera 
90-120 minutes to 
perform correctly. 
Maximal sweating 
is achieved within 
30–65 minutes. 
Unclear Helpful data on the 
TST available in 
DSPN mainly from 
the autonomic lab at 
the Mayo Clinic, 
Rochester USA. 
Patients may not be able to 
tolerate 60 minutes of 
warming up  
Sympathetic 
Skin Response 
Sudomotor 
Non-invasive, 
quantitative 
Information on 
skin autonomic 
function  and 
evaluation of 
postganglionic 
sudomotor 
function using 
electrodermal 
activity 
Purpose built 
lab, SSR 
equipment 
includes 
electrodes. 
45-60 minutes to 
complete. 
Normative data 
available from 
specific centres 
but usually has 
been derived 
from a small 
normative group 
Minimal data only 
available in DSPN. 
Some helpful data 
in  diabetic 
autonomic 
neuropathy and 
bladder 
dysfunction.  
Limited availability, needs 
expertise and experience to 
test correctly. Popular in 
Japan. 
Sudoscan® Sudomotor 
Non-invasive, 
quantitative 
Testing  is based 
on stimulation of 
sweat glands by a 
low-voltage 
current (<4volts) 
representing a  
electrochemical 
reaction between 
electrodes and 
chloride ions,  
Just the 
Sudoscan® 
device 
Takes less than 5 
minutes 
Comes with 
inbuilt normative 
data. Limited 
experience at the 
moment 
Increasing literature 
now available of its 
use in DSPN. 
Similar AUC as 
IENFD (0.761) in 
one study.  For 
Cardiac autonomic 
neuropathy 
sensitivity was 
65%, specificity 
80%.  
 
Still limited availability . 
Needs more detailed 
validation work for different 
ethnicities.  
Reproducibility is yet to be 
established. 
Longitudinal data is lacking. 
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Neuropad® Simple 
qualitative 
indicator of 
sudomotor 
dysfunction 
Simple sticker 
which changes 
colour in the 
presence of 
sweating. 
Relatively 
cheap and easy 
to avail. Cost is 
approximately 
£8/pad.  
Takes less than 10 
minutes 
Qualitative, does 
not need 
normative data.  
Lots of available 
literature and has 
been validated 
against IENFD. In 
one study, 
Neuropad had a 
sensitivity 85% and 
specificity of 45% 
for detection of 
clinical DSPN.  
Difficult to interpret when 
there is partial change in 
colour though. One centre 
has published  data on semi-
quantification using digital 
imaging of the Neuropad®.  
Cardiovascular 
Autonomic 
tests 
Quantitative 
and assess 
cardiac 
autonomic 
neuropathy 
Complex 
laboratory 
based testing 
protocols 
 
Special labs, 
equipment and 
expertise in testing. 
Usually undertaken 
by 
Neurophysiologists 
Takes up to 90-120 
minutes. 
Simpler algorithms 
may take less time 
(30-45 minutes) 
No worldwide 
reference values, 
each laboratory 
tends to have its 
own values 
 Not easily available to 
frontline clinicians. 
Mainly a tool for research in 
DSPN or helpful in 
extremely atypical cases. 
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3.0 The LDIflare technique  
 
The laser Doppler imager flare (LDIflare) is a novel non-invasive method for the 
detection of small fibre neuropathy, based on measurement of the axon-reflex 
mediated vasodilatory flare response, using skin heating as the nociceptive stimulus. 
This neurogenic vasodilatory response has been shown to be directly related to small 
nerve fibre and in particular, c-fibre function [64-66]. The axon reflex is part of the 
Lewis triple response which was first described by Sir Thomas Lewis in 1924 [67]. 
This response can be elicited by drawing a sharp object (a key) across the skin and 
comprises of three phases: 
1) Red reaction or the Flush: This occurs in the first few seconds post injury and 
visually appears as a red line at the site of injury. It is due to capillary dilatation 
secondary to histamine release. 
2) Wheal: This is localized ( to around the region of the redline) and is due to 
increased capillary permeability and exudation of fluid from dilated arterioles, 
capillaries and venules driven by the local histamine release and appears 
approximately 30 seconds  to 1 minute after the initial injury. 
3) Flare: Spreading redness, extending beyond the redline, secondary to the axon 
flare reflex.  
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Figure 1: The Lewis Triple Response. 
In panel:  A) the skin is injured with a key resulting in a pink flush;  B) Wheal 
developing immediately as a direct response and C) Flare response secondary to 
activation of the local small fibre network. 
 
3.1  Principle of LDIflare technique 
  
Stimulation of nociceptive C-fibres leads to the simultaneous conduction of impulses 
orthodromically to the spinal cord and antidromically to the nerve endings abutting 
arterioles, where the release of neurovascular transmitters causes vasodilatation and 
increased blood flow to injured tissues [68]. Substance P and Calcitonin Gene 
Related Peptide (CGRP) are the two main neurovascular transmitters that are 
released from C-fibres and cause vasodilatation of the arteriolar blood vessels 
innervated by the neural network [69].  Substance P acts on its preferred receptor, the 
NK1 receptor and on endothelial cells to cause plasma leakage [70]. Substance P 
also degranulates mast cells, causing the release of mast cell amines. These together 
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with the stimulatory activity of CGRP acting on its receptor contribute to arteriolar 
dilatation [71-72]. The neural course of the axon- reflex is illustrated in Figure 2. 
The resultant flare response may be detected visually, and objectively quantified 
using the laser Doppler imager (LDI). 
 
 
 
Figure 2: Principle of the LDIflare technique. 
The course of the nerve axon-reflex and the antidromic conduction into the adjacent 
blood vessels is picked up by the laser Doppler imager.  
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3.2 Interpreting the results 
 
Baseline perfusion 
 
 
Figure 3: Baseline perfusion in the foot skin prior to a skin stimulus being applied.  
On the right, is a representative B&W image of the scanned area. Using the palette 
provided one can see that the perfusion in this image is <100PU in most of the 
scanned area. 
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Post Stimulation change in perfusion and flare response 
 
 
 
Figure 4: The post stimulation (skin heating) laser Doppler image acquired using a 
LDI.  
The image analysis palate has been set such that flux < 100PU appears as dark blue 
(representing standard blood flow) and anything >300PU appears as bright red. The 
arrows point to the position where the skin heater was applied. 
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Measurement of the LDIflare area. 
 
 
 
 
 
Figure 5: Calculation of the LDIflare area. 
The white freeform constitutes the area of the post skin heating resultant flare 
(LDIflare) and is expressed in cm
2
. The area under the heater (black circle) 
represents the  area  directly under the heater probe and the change in perfusion is 
non-neurogenic and endothelium dependent. It is termed LDImax and is a measure 
of endothelial function. The area outside the skin heating is the true axon-reflex 
mediated flare (LDIflare).  
White Freeform= LDIflare area, cm
2
 Black circle= skin heating area, 1 cm
2
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3.3 LDIflare and Small Fibre Function 
 
The original methodology  of the LDIflare (oLDIflare) was described in 2004 [73] . 
Initial validation demonstrated good reproducibility along with an ability to detect 
early neuropathic abnormalities, even when QST's were normal [73-74]. In a select 
cohort of impaired glucose tolerant individuals without clinical neuropathy, the 
oLDIflare demonstrated evidence of small nerve fibre dysfunction [75]. At the same 
time, a group of patients with longstanding type 1 diabetes, specifically selected for 
the absence of any micro/macrovascular complications demonstrated normal small 
fibre function. Discussing these findings in an editorial, Prof. Boulton and Prof. 
Malik, highlighted the oLDIflare as a emerging marker of SFN with potential for 
application in longitudinal cohorts and neuropathy drug trials [76].  The Toronto 
Consensus on Diabetic Neuropathy also provided further recognition but suggested 
that further studies were required to validate the technique and develop its diagnostic 
potential [31]. In order to achieve this, the methodology needed addressing to make 
the oLDIflare more practical and accessible - testing took  90 minutes to complete - 
making examination of large patient numbers difficult. It was unclear if the original 
heating temperature of 44ᵒC fully stimulated  the small nerve fibres and there were 
additional validity concerns regarding its specificity as a marker of small fibre 
function. Furthermore, it lacked normative data and precise operating characteristics 
for the detection of diabetic neuropathy - important attributes required for clinical 
application.   
In order to overcome these challenges, modifications were made to the methodology 
to allow the testing procedure to be completed faster and further validation studies 
undertaken using the modified LDIflare technique (mLDIflare).   
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4.0 Synopsis of Studies included in this submission 
In this section, I have provided a brief synopsis of the studies included in this 
submission. They include experiments conducted to validate the LDIflare 
methodology, determination of normative values and  operating characteristics such 
as sensitivity and specificity for the detection of clinical diabetic neuropathy. A 
further study examining the relationship of fasting triglycerides in normal glucose 
tolerant on small fibre function is described. In addition, in a group of individuals 
with type 1 diabetes, normal small fibre function is demonstrated in the absence of  
clinical microvascular disease elsewhere. 
 
4.1  Modification and validation of the  LDIflare  technique. 
 
The primary modifications to the LDIflare methodology were: 1) the shortening of 
the acclimatisation period, 2) reducing the duration of skin heating required to elicit 
a nociceptive response, thus allowing the process to be completed faster, and 3) 
utilising a higher final skin heating temperature. The methodology is detailed in the 
papers submitted. The neurogenic nature of the mLDIflare was confirmed in a study 
in which a local anaesthetic cream (EMLA; lidocaine 2.5% and prilocaine 2.5%; 
AstraZeneca, Luton, UK) was applied over the heating area prior to eliciting the 
mLDIflare. The axon-mediated flare response was near completely obliterated 
(9.3±3.0 cm
2
 before and 1.7±0.3 cm
2
 after; p < 0.0001), confirming the neurogenic 
nature of the LDIflare. In another study it was shown that there was near perfect 
correlation of flare sizes between the right and left feet (Pearson’s coefficient  r= 
 0.95, p<0.0001). Finally, and in agreement with the original technique, the 
mLDIflare was significantly lower in the group with diabetic neuropathy (DN+) 
compared to healthy controls (HC) (1.99±1.1 cm
2
 v 9.9±3.4 cm
2
; p<0.001) and also 
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when the DN+ group was compared to those without diabetic neuropathy (DN-) 
(1.99±1.1 cm
2 
v 6.78±2.78 cm
2
; p<0.001) [73].  
 
4.2 Estimating the rate of decline in  LDIflare small fibre function assessed 
and developing age-related centile values in the  detection of clinical 
neuropathy. 
The peripheral nervous system, both somatic and autonomic, changes with age [48, 
58, 77-78] . Determination of accurate normative values underpins the diagnostic 
validity and overall performance of a test [79].  Given the potential role of the 
LDIflare in future testing of early DSPN, it was essential to understand the variables, 
both clinical and metabolic, that influence it.  It was also important to establish 
operating characteristics, such as sensitivity and specificity to determine what values 
can be confidently defined as 'abnormal'. Therefore, studies were undertaken to 
establish determinants of small fibre function as assessed by the LDIflare method 
and derive age-related centile values. An additional aim was to determine which of 
the two analytical techniques, receiver -operator derived cut-off values or centile 
based values, were superior in assessing the operating characteristics of the LDIflare. 
Therefore, across-sectional cohort of 94 healthy volunteers was recruited to 
understand the variables that influence the LDIflare and develop age-specific 
normative values. Glucose dysregulation was excluded using a composite of fasting 
glucose <6.0 mmol/L and HbA1c <6.0% (42 mmol/mol). 
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4.3 Additional validation of the LDIflare 
 
The two studies described below were not specifically designed to validate the 
LDIflare. They provide crucial supportive literature evidence for the LDIflare as a 
useful SFN marker, but are not part of the thesis submission. 
4.3.1 LDIflare and point-of-care nerve conduction device (NC-
stat®|DPNCheck™) for the measurement of early diabetic Neuropathy 
 
More recently, a simple point-of-care device (POCD) has been developed and 
validated for the detection of sensory changes in the sural nerve and to serve as an 
acceptable proxy to NCS [80]. The hand-held device:  NC-stat
®|DPNCheck™ 
system (developed by Neurometrix, Waltham, MA) allows the quantitative 
measurement of sural nerve conduction velocity (SNCV) and amplitude of the 
sensory nerve action potential (SNAP). Validation studies have suggested that it has 
excellent correlation with conventional NCS (r=0.95, p<0.001) and is reliable (inter-
rater reproducibility values  of 0.83 for SNAP  and 0.79 for SNCV) [80-81].  In 
addition, the sensitivity and specificity for identification of DSPN defined by 
electrophysiological criteria was 95% and 71% respectively [81]. 
The accuracy of the NC-Stat
®|DPNCheck™ was compared with the modified 
LDIflare technique for the detection of DSPN categorised into no  (0-2), mild (3-5), 
moderate (6-8) and severe (9-10) DSPN using the neuropathy disability score (NDS) 
[82].  A total of 80 healthy controls (HC) alongside 162 diabetic individuals (50% 
type 1 diabetes) were recruited. All groups were age (p=0.22) and gender (p=0.57) 
matched. Among HC, the LDIflare correlated strongly with both SNAP (r=0.88, 
p<0.0001) and SNCV (r=0.90, p<0.0001). Similar significant correlation between  
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the LDIflare and POCD measures were noted within the no, mild, moderate and 
severe DSPN groups [82].  The LDIflare was significantly smaller among those with 
DM when compared to HC (5.81±2.09 vs. 9.11± 2.17 cm
2
, p<0.0001). The results 
with the POCD were similarly significantly lower in the DM cohort - SNCV 
(42.04±9.11 vs. 50.24±5.69 m/s; p=<0.0001) and SNAP (10.13±3.12 vs. 18.49±4.13 
µV; p=<0.0001). In addition, the LDIflare and POCD both demonstrated individual 
reduction in mean values across the DSPN categories [82].  However, while  there 
was a highly significant difference in the LDIflare sizes between the HC and the 
diabetic control group (those with NDS 0-2) (9.11± 2.17
  
vs 7.52 ± 2.59 cm
2
, p < 
0.0001) there was no such difference between the same groups for SNAP (18.49 ± 
4.13 vs 16.61± 8.45, p=0.15) and SNCV (50.22 ± 5.69 vs 48.95 ± 12.70, p=0.11) 
[82]. The  AUC for the LDIflare and POCD were as follows (Table 3, data extracted 
from Sharma et al [82]). 
AUC  
(Area under the 
curve) 
No DSPN Mild DSPN Moderate 
DSPN 
Severe DSPN 
LDIflare 0.901 0.768 0.767 0.964 
SNAP 0.868 0.703 0.804 0.869 
SNCV 0.896 0.743 0.814 0.907 
 
Table 3: The area under the curve for LDIflare for detection of DSPN categories. 
 
 
4.3.2 The LDIflare in  chemotherapy-induced peripheral neuropathy  
 
A common, unpredictable and at times dose limiting complication of cancer drug 
treatment regimes is the chemotherapy-induced peripheral neuropathy (CIPN). The 
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symptoms of CIPN such as  paraesthesia, dysaesthesia, hyperalgesia, hypoalgesia 
and patients are similar to those described in DSPN. Patients may also experience at 
the same burning, shooting or electric-shock type discomfort described in diabetic 
neuropathic pain [83]. Furthermore, like DSPN, the distribution of symptoms is in a 
“stocking and glove” manner, due to the vulnerability of the long nerves [84]. The 
diagnosis of CIPN is clinical as there is no specific test. However, it is understood 
that IENFD depletion occurs early despite normal peripheral nerve axon counts and 
preserved nerve conduction results and may at times be the only hallmark of CIPN 
[83, 85].  
The LDIflare was evaluated  24 patients with established CIPN and distal sensory 
symptoms to determine its  utility in assessing the diagnosis [86].  Of these, 12 were 
CIPN secondary to platinum analogues and 12 with damage from taxanes. An 
additional 24 age, gender and BMI matched healthy controls were also studied. 
Apart from the LDIflare, additional neurological assessments included determination 
of vibration perception thresholds (VPT), sural nerve amplitude (SNAP) and 
conduction velocity (SNCV) [86]. The LDIflare was significantly reduced in CIPN 
group compared to HC (3.75 ±1.68 vs 6.53 ±0.75 cm
2 
, p<0.001) while SNAP (p= 
0.06 and SNCV (P = 0.09) were not [86]. Additionally, the LDIflare was the only 
neurological marker to correlate with European Organisation for Research and 
Treatment of Cancer - QLQ-CIPN20 disease severity questionnaire [86]. 
4.4  LDIflare small fibre function in normal glucose tolerant subjects with 
and without hypertriglyceridaemia  
The relationship between early diabetic neuropathy and dyslipidemia, and 
hypertriglyceridaemia in particular, is receiving increasing attention. However, the 
relationship between small nerve fibres and triglycerides (TG) in neurologically 
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asymptomatic glucose tolerant individuals remains unclear. Neuropathy studies in 
non-diabetic individuals have either focussed on small cohorts with marked  
hypertriglyceridaemia (HTG) [87-89], or  on those referred to  hospital with overt 
positive sensory neurological symptoms [88, 90-91]. Furthermore, such studies have 
typically utilised large fibre assessments. Therefore, we explored the relationship of 
TG's  on small fibre function, measured using the LDIflare, in groups with 
normotriglyceridaemia (HC), mild hypertriglyceridemia (MiTG, TG=1.7 and 2.25 
mmol/L) and significant hypertriglyceridemia  (HiTG , TG=>2.25 mmol/L) [92]. A 
total of 79 age-matched subjects  (HC=43, MitG=17 and HiTG=19) and were 
selected for normal glucose tolerance and absence of  metabolic syndrome (Met-S) 
as defined by International Diabetes Federation (IDF) [92]. 
Analysis of variance (ANOVA) between the 3 groups showed that total cholesterol, 
Log10 converted triglycerides and TC/HDL ratio differed significantly (F-statistic - 
8.6, 110.0, 15.9 respectively,  p<0.0001). LDL-C also differed between the groups 
(F-statistic 4.6, p=0.01). Post-hoc analysis showed no significant difference in total 
cholesterol, LDL-C, HDL-C or TC/HDL ratio between MiTG and HiTG groups. 
However, the difference in  Log10 converted triglycerides remained significant [92]. 
For all 3 groups combined, there was a significant inverse association between 
LDIflare and age ( r=-0.42, p<0.0001),  BMI (-0.51, p<0.0001), log10 triglycerides 
(r=-0.66,p<0.0001,), total cholesterol (r=-0.26, p=0.02) and TC/HDL ratio (r=-0.37, 
p=0.002). However,  on  multivariate regression analysis, only log10 triglycerides (B 
coefficient -5.8, 95% CI -7.5 to -4.2, p<0.0001) and age (-0.08, 95% CI -0.13 to -
0.03, p=0.003) were independently associated . A similar association for age (B- 
coefficient -0.10, 95% CI -0.18 to -0.02, p=0.02) and Log10 triglycerides (B- 
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coefficient -5.0, 95% CI -7.9 to -2.1, p=0.01) was noted when the MiTG and HiTG 
groups were combined. 
4.5  Small fibre dysfunction, microvascular complications and glycaemic 
control in type 1 diabetes: a case-control study  
 
The relationship of microvascular disease and small fibre function was investigated 
using the LDIflare in a group of type 1 diabetic individuals of moderate duration of 
disease with  (MV+) and without (MV-) microvascular complications and compared 
to healthy controls (HC) [93]. Each group consisted of 24 individuals without overt 
clinical neuropathy (neuropathy disability score, NDS <3 and Toronto clinical 
neuropathy score, TCNS <5).  Subjects with type 1 diabetes were considered to have 
microvascular disease if they had either confirmed diabetic retinopathy  for at least 2 
years' duration as per the English National Screening Programme for Diabetic 
Retinopathy [94] and/or microalbuminuria (urinary albumin to creatinine ratio >2.5 
mg/mmol for males and >3.5 mg/mmol for females). In addition, duration-averaged 
HbA1C was calculated in all participants by calculating the mean of their HbA1C 
recorded at annual review assessments over the period they had diabetes [74].  
The 3 groups  (HC, MV- and MV+) did not differ for sex, age, height, weight or 
BMI. The duration of diabetes was not significantly different between the two type 1 
groups  (MV- 17.7±5.7 years versus MV+  20.1±5.2 years, p=0.21). The HbA1C 
values at the point of LDIflare estimation were also similar (MV- 8.0±1.2% [64±10 
mmol/mol] versus  MV+ 8.0±0.9% [64±9 mmol/mol], p=0.53). Neither of the above 
HbA1C correlated with LDIflare. However, the duration-averaged HbA1C was 
significantly higher in the MV+ group ( MV+ 8.6±0.9% [70±9 mmol/mol] versus 
MV− 7.6±0.6% [60±7 mmol/mol], p<0.001). Combining  the two diabetic groups, 
45 
 
there was a significant inverse correlation  between the LDIflare size and duration-
averaged HbA1C, (r= -0.50, p<0.001) which persisted after adjustment for age, BMI, 
and lipids [93].      
 The LDIflare size did not differ between the HC and MV- groups ( HC 10.0±3.09 
cm
2
 versus MV- 9.9±2.9 cm
2
, p=0.55). However, the LDIflare size was significantly  
lower in the MV+  group (5.1±1.8 cm
2
) when compared to HC (p<0.0001) and MV- 
(p<0.001) groups. The LDImax, which relates to the area directly under the heater 
probe and a measure of non-neurogenic vasodilatation, was not significantly 
different between the MV- and MV+ groups (MV- 685±141 PU versus 632±156 PU, 
p=0.10) [74]. The MV+ demonstrated a higher fasting triglyceride concentration 
compared to the MV- group ( MV+ 1.23±0.12 mmol/l versus MV− 0.92±0.07, 
p=0.04). There was no intra-group correlation between LDIflare size and any of the 
lipid parameters including triglycerides. However, when the MV- and MV+ groups 
were combined, after adjusting for age, gender and BMI, the LDIflare inversely 
correlated with triglycerides  (r= -0.304, p=0.036). 
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 5.0 Discussion 
 
Measurement of small fibre nerve impairment is a major challenge. While studies in 
diabetic retinopathy and nephropathy have had access to clinically relevant 
indicators of early abnormalities such as digital retinal images and urine albumin 
excretion rate estimation, no such reliable marker of early damage exists in 
neuropathy. Although, small fibre abnormalities are increasingly recognised as the 
earliest to be acquired and may potentially present a higher regenerative ability, the 
lack of accessible tools to quantitate such damage has been a limitation. Hence, 
studies looking into fundamental clinical questions such as - does good glycaemic 
control impact on neural function - have had to rely on indicators of more established 
peripheral nerve involvement such as vibratory sensation, light touch or ankle 
reflexes [95]. This may be a major reason for the failure of putative pharmacological 
interventions to demonstrate a reduction in relative risk for nerve events, especially 
in type 2 diabetes [34, 95]. It also has meant that the natural course and history of 
diabetic neuropathy continues to remain poorly understood.    
The data presented in this thesis validates the modifications to the LDIflare and 
confirms that it is a novel, non-invasive,  reproducible and importantly, an objective 
marker of small fibre function thereby fulfilling an important niche in small fibre 
testing. The coefficient of variation (CoV) was 11% and compared well with the 
original methodology which was between 12 and 15% [75]. The testing process can 
be completed in less than 30 minutes, thus allowing subjects to be assessed relatively 
quickly and is similar to the testing time required to perform a nerve conduction 
study. This specification, in particular, will allow for its application in studies with 
larger cohorts. Additionally, the testing site is directly representative of the most 
clinically relevant pathological site in DSPN. The analysis of the results obtained is 
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straightforward and unlike IVCCM or CHEPS, there is only one neurogenic variable 
to analyse. The non-invasive nature allows for the test to be repeated as many times 
as required. Finally, the simplicity of the testing process, allows for the procedure to 
be carried out in a clinic environment without the need for complex, purpose built 
laboratory space. It is of note that after a short period of training all 5 researchers in 
the Ipswich Diabetes Research unit have achieved CoV of less than 15%. A potential 
disadvantage of the method is the cost of the LDI scanning device, however this is 
on par with the cost of a IVCCM or a CASE-IV™ QST device.  
The clinical translation of any technique is dependent on the definition of clear 
normative values, allowing for the determination of whether a condition is present or 
absent.  It is also important to understand the various factors that influence a 
particular technique, as statistical adjustments may need to be undertaken, especially 
in longitudinal studies, to evaluate potential epoch and cohort effects [79]. If age, as 
a dependent variable plays a significant role, then it is important that the test results 
are interpreted accordingly. For example, if there is a significant inverse relationship 
with age, what may be abnormal value for a young individual, may be well within 
the normal range in the elderly. Age was a major determinant of small fibre function 
as assessed by the LDIflare [78] (Figure 6). In addition, fasting triglycerides but not 
total cholesterol or LDL-Cholesterol was an independent predictor.  
The relationship of small fibre indices with age are in keeping with findings reported 
by the worldwide normative reference study on IENFD [48] as well as the recently 
published multinational normative data on IVCCM values [58]. Normative values of 
small fibre function markers such as contact heat evoked potential (CHEPS) [96] as 
well as laser evoked potentials (LEPs) [97] have also demonstrated a similar 
association with age. The lack of influence of height, weight, body mass index 
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(BMI), HbA1C (within the normal range) on SFN indices has also been reported 
previously [48, 58]. Other normative datasets have noticed a gender association [48, 
96, 98], however,  we did not find such an association. Although the LDIflare 
elicited larger flare sizes in females, the difference did not reach statistical 
significance [78]. This may be partly explained by the relatively moderate size of our 
normative sample and  similar sized cohorts in IVCCM  and laser evoked potential 
studies have not demonstrated a gender effect [99-100]. Importantly, the consistent 
influence of age in almost every published study underscores the need for all small 
fibre markers to have clear age-determined normative values [101].  
 
 
Figure 6: Normogram of the LDIflare. 
 
The LDIflare demonstrated excellent sensitivity and specificity for the detection of 
DSPN and compares favourably with other established small fibre markers. Using 
NDS>3 to stratify the presence of DSPN, IVCCM has a reported sensitivity of 82% 
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and specificity of 52% [57]. The sensitivity and specificity for the original LDIflare 
has been reported by other groups.  Nouri et al, measured the LDIflare in a group 
with type 1 diabetes and in healthy controls. Using the subclinical sural nerve 
impairment based criteria as reference standard, and employing the original LDIflare 
(heating to 44°C for 20 minutes) they found a sensitivity of 79% and a specificity of 
60% with an area under the curve (AUC) of 0.75 for a cut off value of 1.90 cm
2 
[102]. In the same study using the 'England criteria' [103] as reference standard,  the 
sensitivity and  specificity were 66% and 70% respectively, with AUC 0.72 for  a cut 
off value of 1.90 cm
2
 [102].  In a cohort of 74 subjects with idiopathic small fibre 
painful neuropathy (with normal nerve conduction studies), Ebadi et al, using  
IENFD cut-off of <5.4 fibres/mm as the reference standard for the presence of  SFN, 
estimated the sensitivity and specificity of the LDIflare at 54% and 54% 
respectively, giving an AUC of 0.54 at a diagnostic threshold of 1.96 cm
2
 [104].  
However, there are important differences between the methodology used by Nouri et 
al and Ebadi et al and those of the studies undertaken in this thesis. A major 
limitation of these studies, both of which originated from the same research unit, was 
the lack of clarity in the LDIflare methodology and the absence of  published data on 
the reproducibility values for the LDIflare technique in their hands. In addition, a 
smaller size heating probe was used. The mean flare sizes of 2.1 ± 1.1 cm
2
 and 2.3 ± 
1.2 cm
2
 their studies were much smaller than those obtained in the original studies in 
the Ipswich unit (5.2 cm
2
 (IQR 3.9 –5.9 cm2) possibly reflecting the different in 
probe size and/or lack of appreciation in the importance of scrupulous attention to 
acclimatisation and precision of technique which is required to achieve 
reproducibility. This may have contributed to the inconsistent operating 
characteristics reported. Furthermore, and importantly, their flare sizes are far from 
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those observed with the modified LDIflare technique. More recently, the same team 
has investigated the utility of LDIflare testing in individuals presenting to a 
neuromuscular clinic with typical positive neuropathic symptoms in the lower limbs, 
of which 26% had diabetes.  [105]. They reported that while the  LDIflare performed 
moderately in all-cause SFN (combined sensitivity 64%), it had excellent 
performance in diabetic mixed fibre neuropathy (sensitivity 86%) with demonstrable 
superiority  over quantitative thermal thresholds (sensitivity 36% for cooling  and 
0% for heat thresholds for all cause SFN and 79% and 29% for diabetes respectively) 
[105]. All individuals with reduced IENFD also had reduced LDIflare [105] 
The studies using the NC-Stat
®|DPNCheck™  and in subjects with CIPN provide 
additional validation of the LDIflare technique. Indeed, the strong AUC (0.901) for 
those without clinical DSPN suggests that the LDIflare also possesses a strong 
negative predictive value for DSPN. Furthermore, they demonstrate a strong 
correlation with sensory nerve conduction parameters, which are themselves the 
earliest perceptible large fibre changes [31]. The finding of normal sural sensory 
nerve conduction among those without clinical DSPN but abnormal LDIflare adds 
further to the suggestion that small fibre dysfunction may precede changes in large 
fibre markers. In another context, the ability of the LDIflare to detect early small 
fibre change, when traditional neurophysiology is non-contributory or even normal, 
underlines the importance of using tests of small fibre function in future SFN 
research studies.   
The relationship between small fibre function and triglyceride levels is novel and 
intriguing, especially the hitheto unrecognised findings noted in healthy subjects 
and/or in the context of mildly abnormal triglyceride levels. Although the inverse 
correlation in one cross-sectional study cannot determine causality, it does suggest 
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the possibility that triglyceride levels above the normal may have an incremental, 
direct neurotoxic effect on small nerve fibres. The exact mechanism of damage is 
unclear. One hypothesis is that  generation of long chain free fatty acids may damage 
the Schwann cells [106-108] and oxidised or glycated LDL may bind to surface 
receptors and trigger intracellular oxidative stress through a process not dissimilar to 
direct effects of hyperglycaemia [109]. Another possibility is that dyslipidemia may 
drive direct axonal damage by way of mitochondrial dysfunction [110-111]. The 
findings, in part, may explain the presence of neuropathy  in early type 2 diabetes 
(and in prediabetic states) and account for the persistent risk of diabetic neuropathy 
in specific, but microvascular complications in general, despite good glycaemic 
control.  
The relationship between SFN and microvascular disease in type 1 diabetes has 
remained inconclusive. The LDIflare observed abnormal small fibre function in 
those with microvascular disease but preserved function in those without 
microvascular disease. The findings support previous observations in the DCCT [17] 
and EUROBIAB [112] studies that glycaemic control plays a significant role in the 
development diabetic neuropathy of type 1 diabetes and provides specific evidence 
that this also pertains to early small fibre change. However, those studies 
predominantly used history, focussed neurological examination, nerve conduction 
studies and autonomic testing to assess DSPN and did not use any validated SFN 
measure.  
The important role of hyperglycaemia in the aetiopathogenesis of diabetic 
neuropathy is undisputed. Studies have clearly established a link between  diabetes 
and glycaemic control and neuropathy development [10, 109, 113]. Whether the 
effect of hyperglycaemia as the pathogenic driver of early neuropathy is directly 
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mediated (through the polyol pathway, oxidative-nitrosative stress or lack of c-
peptide stimulation) or indirect through the development of neuronal microvascular 
damage remains unclear [109]. Green et al, in an earlier study using the older 
LDIflare technique noted that individuals with type 1 diabetes, carefully selected for 
absence of retinopathy and nephropathy had evidently preserved small fibre 
function, while a group with prediabetes  simultaneously studied, demonstrated 
significant small fibre dysfunction [75].  Studies in type 2 diabetes have noted the 
presence of neuropathy early into the diagnosis of diabetes [18, 25, 114-115] and 
similar findings have also been noted in prediabetes [29, 116-118]. Such individuals 
have relatively mild hyperglycaemia and significantly less exposure to glycaemic 
perturbations than the type 1 groups studied. Taken together, the findings with the 
LDIflare suggest that aetiopathogensis the neuropathies of type 1 and type 2 diabetes 
may be different - that in those with type 2 diabetes, metabolic factors may play a 
significant early role while in those with type 1 diabetes, microangiopathy may be 
key [33, 119] . If these observations are proven, they may have a important 
implications on how patients are recruited for future therapeutic trials of early 
diabetic neuropathy. Putative agents having a significant impact on microangiopathy 
and the microvasculature may need to recruit more subjects with type 1 diabetes ; 
while those with corrective effect on metabolic parameters may be better off with 
recruiting predominantly type 2 diabetes subjects.   
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6.0  Limitations of the papers presented: 
 
Although the experiments and studies presented validate the LDIflare technique and 
highlight the important role of small fibre function in DSPN, they do have 
limitations.  
The stratification of neuropathy was based on the Neuropathy Disability Score 
(NDS). The points accrued in the NDS are based on clinical examination which may 
be subjective with a wide inter-rater variability [120]. Formal nerve conduction 
studies were not undertaken; hence our study subjects did not fulfil the Toronto 
consensus case-definition of confirmed/absent neuropathy. The primary reason is 
that the studies were conceived and ethical approval gained prior to the publication 
of the Toronto consensus. Limited funding for the studies was an additional factor 
for the reliance on NDS. Nonetheless, the use of NDS is in keeping with other 
previously published studies on small fibre neuropathy assessment techniques [57, 
121-123]. Importantly, all the studies presented had a single operator which would 
have significantly reduced any variation in the subsequent stratification. In addition, 
there are only two diabetes groups, those with clinical neuropathy (NDS≥3) and 
those without (NDS<3), in the validation work undertaken. A more detailed 
assessment, allowing the assessment and validation of the modified LDIflare 
technique against neuropathy stratified as mild, moderate and severe using the NDS 
or NIS-LL would have been desirable.   
Another potential limitation is the reliance of a single small fibre measure. However, 
the LDIflare has been previously validated against intra-epidermal nerve fibre 
density and has been shown to have a strong correlation [75]. In the extension of the 
validation studies, a strong correlation with early sensory sural nerve conduction 
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parameters has also been demonstrated [82]. Furthermore, in our experience, the 
utility of quantitative tests of thermal thresholds is limited as they are subjective and 
time consuming [49, 78]. Future studies with the LDIflare should ideally include an 
additional objective SFN marker, such as IENFD or IVCCM to provide additional 
supportive evidence.  
All subjects included in the studies did not have any obvious macrovascular disease. 
Thus, the LDIflare has not been validated for use in this group. Further studies 
would be required to assess suitability of the LDIflare to measure small fibre 
function in this specific group. However, we expect most individuals being assessed 
for early neuropathy not to have significant symptomatic or major structural vascular 
disease, which frequently coexists with advanced stage neuropathy and loss of 
protective sensation. Therefore, this limitation is unlikely to impact on the broad 
applicability of the technique. Future work should evaluate the LDIflare in this 
particular group, to evaluate reliability, validity and importantly, safety.  
Finally, given the complex interplay of microvascular response to nociceptive 
stimuli, some experts have suggested that the LDIflare may be a reflection of the 
underlying microvascular status and endothelial function. The LDIflare measures 
changes in dermal perfusion, but is also dependent on the ability of the underlying 
microvasculature to dilate to the efferent neurogenic stimuli. Vascular tone is 
dependent on extrinsic factors such sympathetic activity (neurogenic tone) [124], 
circulating angiotensin II [125] and intrinsic factors such as smooth muscle 
mechanics, nitric oxide (vasodilator) [126-127], endothelin (vasoconstrictor) [125, 
128], local humoro-chemicals such as histamine, bradykinins [129] and local 
oxygenation [130].  The nerve–axon reflex related vasodilatation has been validated 
as an objective method to evaluate C‐nociceptive fibre function [64, 122, 131-132]. 
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In support of the neurogenic nature of the LDIflare, both thermal and 
pharmacological stimuli have been shown to induce the nerve–axon reflex [65, 133].  
Application of a local anaesthetic agent has been shown to reduce the acetylcholine 
mediated response (endothelium dependent) by 71% ± 12% [64, 134] but not the 
response to sodium nitroprusside (endothelium-independent and a smooth muscle 
relaxant) [134]. In many of the above studies, laser Doppler Flowmetry (LDF) with 
single-point measurement rather than laser Doppler imaging (with scanning of the 
entire response) was undertaken and may have impacted on the conclusions derived. 
Inherently LDF has a much higher coefficient of variation of up to 38%, while we 
have demonstrated a CoV of~11% using the LDIflare. Recently, Emanuel and 
colleagues using the LDF technique alongside nerve conduction studies and IENFD 
measurement have provided additional support for the neurogenic nature  of the 
LDIflare by demonstrating that impaired microvascular endothelium-dependent 
vasodilation does not contribute to neuropathy in type 2 diabetes and vice versa 
[135].   Thus, from a mechanistic perspective, the LDIflare results represent the 
significant (but in certain situations, not exclusive) role of small fibres in the nerve-
axon mediated vasodilatation. 
In our normative studies, and indeed in the two groups of type 1 diabetes, there was 
no correlation between LDIflare and LDImax, the latter which is the direct response 
to skin heating. This is further supportive that the LDIflare indeed quantifies 
neurogenic function. Additionally, application of the EMLA, virtually abolished the 
LDIflare but did not change the LDImax [136]. LDIflare has also been shown to 
correlate with IENFD as well as dermal nerve fibre density [137]. The work by 
Perkins and colleagues using the original LDIflare methodology demonstrated a 
moderate but significant correlation between corneal confocal microscopy markers 
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and the LDIflare ( r= 0.25-0.41, p<0.01) [138]. Comparison with sural sensory 
conduction parameters using the NC-Stat
®|DPNCheck™  demonstrating  a strong 
correlation has provided further evidence for the LDIflare as a surrogate marker of 
diabetic neuropathy [82].  
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7.0 Conclusions and future outlook 
 
The detection of the early forms of DSPN, especially small fibre neuropathy, 
remains a significant challenge. Symptoms, signs and standard neurophysiology 
cannot be relied upon as they primarily reflect large fibre deficits. While a number of 
small fibre techniques are currently available, their widespread application is limited 
either by their invasive nature, poor reproducibility, poor sensitivity, need specialist 
equipment/personnel or a clear lack of normative data.   
7.1 LDIflare as a validated marker of small fibre function 
 
In the series of papers presented, the LDIflare, in its current modification, is 
supported as a novel, relatively rapid, non-invasive, reproducible, reliable and 
accurate marker for small fibre function. This has been achieved by: 
a) Shortening the acclimatisation  and  heating period and by using a  higher 
skin heating temperature, 
b) Determining normative values for the LDIflare  by applying the technique in 
healthy, non-neuropathic adult volunteers categorised into 4 age-groups, 
c) Assessment of operating characteristics such as sensitivity, specificity, 
positive and negative predictive values.  
The current technique is able to detect the same group difference as the original 
method but with greater clarity, given the larger flare sizes in those without or mild 
small fibre dysfunction. Additional validation for the technique has been provided by 
studies comparing the LDIflare with the NC-stat
®|DPNCheck™ device and through 
studies undertaken by other research groups.  
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Emerging work utilising the capsaicin nerve injury model has shown that the axon-
mediated flare area measured with the laser Doppler imager technique, is able to 
consistently demonstrate differences between capsaicin denervated and placebo 
treated skin in addition showing  ability to detect reinnervation by demonstrating an 
improvement in flare area sizes  2 weeks post denervation [139]. These findings, 
while preliminary, can be considered encouraging. as an important value of any 
small fibre test in an interventional study would be its ability to detect a response to 
treatment [22].  
The validation findings in this submission and those available in literature (direct 
and surrogate) demonstrate the potential of  LDIflare as a SFN marker which could 
be reliably utilised in translational studies of future disease modifying therapies in 
diabetic neuropathy. It could also be used in larger cohort studies required to 
understand the epidemiology of diabetic neuropathy and monitor progression. In 
addition, the technique could arguably be also considered ready for clinical use in 
specialist units dealing  in small fibre neuropathy and its diagnosis, as an important 
additional methodology alongside a battery of other tests such as IENFD, IVCCM 
and autonomic function assessments.  
7.2 Small fibre nerves and pathogenesis of diabetic neuropathy 
 
The relationship between small fibre function and microvascular complications in 
neurologically asymptomatic individuals with type 1 diabetes is extremely intriguing 
and is in contrast to findings reported in prediabetes and type 2 diabetes. The 
reporting of preserved small fibre function in those without retinal or renal 
microvascular disease is novel. This supports the hypothesis that the 
aetiopathogenesis of neuropathy may be different in the two forms of diabetes: that 
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in type 2 the initial effects are mediated through metabolic defects while in type 1 
diabetes, vascular injury may be the primary trigger.  
A recent study has noted abnormalities of small fibre structure in type 1 diabetes, 
measured using IVCCM, in those without retinopathy or microalbuminuria [123]. 
These findings are contrary to our findings of preserved LDIflare in type 1 diabetes 
without early renal or retinal abnormalities. The participants in that study had a 
higher NDS score (1.8 ± 0.7 v 0.16±0.5 in our cohort) which may have contributed 
to the findings.  However, another view may be that small fibre nerve damage 
perhaps starts prior to demonstrable abnormalities of retinopathy and nephropathy. 
Within the specialism of small fibre assessment, apart from underscoring the need 
for larger cohort studies of well characterised subjects, the disparity in currently 
published LDIflare and IVCCM findings also lead to the question of which occurs 
first - Small fibre structural or functional damage? To answer this, prospective 
studies simultaneously assessing both small fibre and function in well characterised 
subjects are required.  
The findings of an inverse correlation between small fibre function and triglycerides 
are novel and not been previously reported. The present findings could be considered 
early work and larger cohorts of both normal glucose-tolerant and diabetic subjects 
are required to understand the relationship further. In addition, the LDIflare small 
fibre dysfunction model may have a potential role in understanding the effect of anti-
hyperlipidaemic therapy on progression/reversal of neuropathy.  
  
60 
 
7.3 Future Outlook for the LDIflare 
 
The reliability and operating characteristics of a test are likely to be enhanced with 
increasing numbers of subjects tested allowing apparent any inconsistencies - 
methodological and analytical - to be further improved upon. This is also applicable 
to the LDIflare. Although age-specific normative values have been derived, they will 
be further fortified by the assessment of a larger number of normal glucose tolerant 
(NGT) individuals. This larger sample size may confirm if the LDIflare has an 
association with gender like QST and IENFD and IVCCM and further refine the 
normative data. Ideally, this should be through a worldwide, multicentre 
collaborative effort with other centres using the LDIflare similar to initiatives in 
IENFD [48] and IVCCM [58]. A prospective follow-up study may clarify the annual 
rate of change in the LDIflare in healthy controls and those with diabetes in addition 
to delineating the clinical and biological factors associated with such change. The 
prospective study may also clarify if the LDIflare is able to demonstrate 
improvement in SFF when there is sustained improvement in glycaemic control. 
There is already evidence that IENFD [60, 140] and IVCCM [62, 141] are able to 
detect such a response to treatment.  
Another validation wish list for the LDIflare is to confirm its correlation with formal 
nerve conduction studies. In addition, a direct comparison with all of the IVCCM 
variables, which have emerged over the past decade as simple, reliable and non-
invasive marker of small fibre structure is desirable. This is may further strengthen 
the place of LDIflare as a suitable supplementary endpoint for early neuropathy case 
definition alongside invasive morphometric measure such as IENFD or sural nerve 
biopsy.  
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Currently, there is no single small fibre marker that can be considered as the ‘gold 
standard’. It remains to be seen if the operating characteristics for early DSPN 
detection and for SFN assessment can be enhanced if LDIflare and IVCCM findings 
are combined compared to their individual sensitivities and specificities. It is also 
unclear which of the two - small fibre structure or function - is the first to be 
impaired. The lack of a simple and objective functional marker of SFN has been a 
limiting factor. The LDIflare fulfils, and in conjunction with the IVCCM or IENFD, 
may be suitable for the investigation of this fundamental conundrum.  
One future challenge is that there are now two validated protocols for the LDIflare. 
There is a need for those involved in small fibre research and utilising the LDIflare 
to utilise the best validated method and  promote it, for example as done by  the  
German Pain Network for NCS and QST testing. This will, again, require 
collaborative discussions between various research units that utilise the LDIflare 
technique [142]. The current iteration on account of its simple investigational 
algorithm and short heating duration should be encouraged. With diabetic 
neuropathy research being a domain of relatively select research units, the need for 
multicentre cooperation and standardisation of the technique is important. 
The findings of SFN in those with type 1 diabetes without renal and retinal disease is 
opening up newer paradigms of thought and investigation. These, alongside well 
characterised SFN studies in early type 2 diabetes suggesting that neuropathy may 
occur prior to the development of retinopathy challenge how glucose thresholds are 
used to derive the definition of diabetes, especially type 2 diabetes (143). The current 
diagnostic glucose thresholds have been derived from retinopathy prevalence studies, 
which have rarely included neuropathy measures. If neuropathy precedes 
retinopathy, or indeed simply the presence of neuropathy may change or add an 
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additional dimension to our perception of glucose thresholds. The LDIflare on 
account of its sensitivity may be an useful neuromarker in future studies 
investigating the glycaemic cut-off targets. 
Finally, there is a need to reassign the current definition of DSPN. Many studies, 
including those in this submission, have supported the notion that small fibre 
neuropathy may be asymptomatic. The current Toronto Consensus would classify 
such individuals as subclinical neuropathy, until they developed symptoms or signs, 
even if there was quantitative change in the interim. Furthermore, there is no current 
severity staging system in place for SFN. The LDIflare is objective, quantitative and 
reliable -and will be valuable tool in future studies of severity stratification.   
 
 
63 
 
References: 
[1] World Health Organization (1999) Definition, Diagnosis and Classification 
of Diabetes Mellitus and its Complications: Report of a WHO Consultation. Part 1: 
Diagnosis and Classification of Diabetes Mellitus. Geneva, World Health Org. URL 
http://www.who.int/iris/handle/10665/66040. Accessed 27/10/2017.   
[2] Danaei G, Finucane MM, Lu Y, et al. (2011) National, regional, and global 
trends in fasting plasma glucose and diabetes prevalence since 1980: systematic 
analysis of health examination surveys and epidemiological studies with 370 
country-years and 2.7million participants. The Lancet 378: 31-40 
[3] Tabák AG, Herder C, Rathmann W, Brunner EJ, Kivimäki M (2012) 
Prediabetes: a high-risk state for diabetes development. The Lancet 379: 2279-2290 
[4] Perreault L, Pan Q, Mather KJ, Watson KE, Hamman RF, Kahn SE (2012) 
Effect of regression from prediabetes to normal glucose regulation on long-term 
reduction in diabetes risk: results from the Diabetes Prevention Program Outcomes 
Study. Lancet 379: 2243-2251 
[5] Hex N, Bartlett C, Wright D, Taylor M, Varley D (2012) Estimating the 
current and future costs of Type 1 and Type 2 diabetes in the UK, including direct 
health costs and indirect societal and productivity costs. Diabet Med 29: 855-862 
[6] Kerr, M. (2016) Improving footcare for people with diabetes and saving 
money:an economic study in England. Diabetes UK.  
URL https://diabetes-resources-production.s3-eu-west-1.amazonaws.com/diabetes-
storage/migration/pdf/Improving%2520footcare%2520economic%2520study%2520
%28January%25202017%29.pdf. Accessed 27/10/2017 
[7] American Diabetes Association (2013) Economic Costs of Diabetes in the 
U.S. in 2012. Diabetes Care 36: 1033-1046 
[8] Partanen J, Niskanen L, Lehtinen J, Mervaala E, Siitonen O, Uusitupa M 
(1995) Natural history of peripheral neuropathy in patients with non-insulin-
dependent diabetes mellitus. N Engl J Med 333: 89-94 
[9] Pop-Busui R, Boulton AJM, Feldman EL, et al. (2017) Diabetic Neuropathy: 
A Position Statement by the American Diabetes Association. Diabetes Care 40: 136-
154 
[10] Boulton AJ, Vinik AI, Arezzo JC, et al. (2005) Diabetic neuropathies: a 
statement by the American Diabetes Association. Diabetes Care 28: 956-962 
64 
 
[11] Maser RE, Mitchell BD, Vinik AI, Freeman R (2003) The Association 
Between Cardiovascular Autonomic Neuropathy and Mortality in Individuals With 
Diabetes: A meta-analysis. Diabetes Care 26: 1895-1901 
[12] Ziegler D, Zentai CP, Perz S, et al. (2008) Prediction of mortality using 
measures of cardiac autonomic dysfunction in the diabetic and nondiabetic 
population: the MONICA/KORA Augsburg Cohort Study. Diabetes Care 31: 556-
561 
[13] Vas PR, Edmonds ME (2016) Early recognition of diabetic peripheral 
neuropathy and the need for one-stop microvascular assessment. Lancet Diabetes 
Endocrinology 4(9): 723-725. 
[14] Armstrong DG, Wrobel J, Robbins JM (2007) Guest Editorial: are diabetes-
related wounds and amputations worse than cancer? International Wound Journal 4: 
286-287 
[15] Gordois A, Scuffham P, Shearer A, Oglesby A (2003) The healthcare costs of 
diabetic peripheral neuropathy in the UK. The Diabetic Foot Journal 6: 62-73 
[16] Malik RA (2016) Wherefore Art Thou, O Treatment for Diabetic 
Neuropathy? Int Rev Neurobiol 127: 287-317 
[17] Martin CL, Albers JW, Pop-Busui R (2014) Neuropathy and Related 
Findings in the Diabetes Control and Complications Trial/Epidemiology of Diabetes 
Interventions and Complications Study. Diabetes Care 37: 31-38 
[18] Ziegler D, Papanas N, Zhivov A, et al. (2014) Early detection of nerve fiber 
loss by corneal confocal microscopy and skin biopsy in recently diagnosed type 2 
diabetes. Diabetes 63: 2454-2463 
[19] Sumner CJ, Sheth S, Griffin JW, Cornblath DR, Polydefkis M (2003) The 
spectrum of neuropathy in diabetes and impaired glucose tolerance. Neurology 60: 
108-111 
[20] Azmi S, Ferdousi M, Petropoulos IN, et al. (2015) Corneal Confocal 
Microscopy Identifies Small-Fiber Neuropathy in Subjects With Impaired Glucose 
Tolerance Who Develop Type 2 Diabetes. Diabetes Care 38(8): 1502-1508. 
[21] Abbott CA, Carrington AL, Ashe H, et al. (2002) The North-West Diabetes 
Foot Care Study: incidence of, and risk factors for, new diabetic foot ulceration in a 
community-based patient cohort. Diabet Med 19: 377-384 
[22] Malik RA (2014) Why are there no good treatments for diabetic neuropathy? 
The Lancet Diabetes & Endocrinology 2: 607-609 
65 
 
[23] Vallbo AB, Hagbarth K, Torebjork H, Wallin B (1979) Somatosensory, 
proprioceptive, and sympathetic activity in human peripheral nerves. Physiological 
Reviews 59: 919-957 
[24] Ziegler D, Mayer P, Gries FA (1988) Evaluation of thermal, pain, and 
vibration sensation thresholds in newly diagnosed type 1 diabetic patients. J Neurol 
Neurosurg Psychiatry 51: 1420-1424 
[25] Loseth S, Stalberg E, Jorde R, Mellgren SI (2008) Early diabetic neuropathy: 
thermal thresholds and intraepidermal nerve fibre density in patients with normal 
nerve conduction studies. J Neurol 255: 1197-1202 
[26] Breiner A, Lovblom LE, Perkins BA, Bril V (2014) Does the prevailing 
hypothesis that small-fiber dysfunction precedes large-fiber dysfunction apply to 
type 1 diabetic patients? Diabetes Care 37: 1418-1424 
[27] Jimenez-Cohl P, Grekin C, Leyton C, Vargas C, Villaseca R (2012) Thermal 
threshold: research study on small fiber dysfunction in distal diabetic 
polyneuropathy. J Diabetes Sci Technol 6: 177-183 
[28] Singleton JR, Smith AG, Bromberg MB (2001) Painful sensory 
polyneuropathy associated with impaired glucose tolerance. Muscle Nerve 24: 1225-
1228 
[29] Nebuchennykh M, Loseth S, Jorde R, Mellgren SI (2008) Idiopathic 
polyneuropathy and impaired glucose metabolism in a Norwegian patient series. Eur 
J Neurol 15: 810-816 
[30] Divisova S, Vlckova E, Hnojcikova M, et al. (2012) Prediabetes/early 
diabetes-associated neuropathy predominantly involves sensory small fibres. J 
Peripher Nerv Syst 17: 341-350 
[31] Tesfaye S, Boulton AJ, Dyck PJ, et al. (2010) Diabetic neuropathies: update 
on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes 
Care 33: 2285-2293 
[32] Umapathi T, Tan WL, Loke SC, Soon PC, Tavintharan S, Chan YH (2007) 
Intraepidermal nerve fiber density as a marker of early diabetic neuropathy. Muscle 
Nerve 35: 591-598 
[33] Sima AAF, Kamiya H (2006) Diabetic Neuropathy Differs in Type 1 and 
Type 2 Diabetes. Annals of the New York Academy of Sciences 1084: 235-249 
66 
 
[34] Callaghan BC, Little AA, Feldman EL, Hughes RA (2012) Enhanced glucose 
control for preventing and treating diabetic neuropathy. Cochrane Database Syst Rev 
6: CD007543. DOI 10.1002/14651858.CD007543.pub2 
[35] Stino AM, Smith AG (2017) Peripheral Neuropathy in Prediabetes and the 
Metabolic Syndrome. Journal of Diabetes Investigation 8(5):646-655. doi: 
10.1111/jdi.12650 
[36] Løseth S, Stålberg EV, Lindal S, Olsen E, Jorde R, Mellgren SI (2016) Small 
and large fiber neuropathy in those with type 1 and type 2 diabetes: a 5-year follow-
up study. Journal of the Peripheral Nervous System 21: 15-21 
[37] Gibbons CH, Freeman R, Tecilazich F, et al. (2013) The evolving natural 
history of neurophysiologic function in patients with well-controlled diabetes. 
Journal of the Peripheral Nervous System 18: 153-161 
[38] Sachedina S, Toth C (2013) Progression in idiopathic, diabetic, 
paraproteinemic, alcoholic, and B12 deficiency neuropathy. Journal of the Peripheral 
Nervous System 18: 247-255 
[39] Polydefkis M, Arezzo J, Nash M, et al. (2015) Safety and efficacy of 
ranirestat in patients with mild-to-moderate diabetic sensorimotor polyneuropathy. J 
Peripher Nerv Syst 20: 363-371 
[40] Bril V (2016) Chapter Three - The Perfect Clinical Trial. In: Nigel AC, Paul 
F (eds) International Review of Neurobiology. Academic Press, pp 27-41 
[41] Calcutt N, Fernyhough P (2016) Chapter One - A Brief Introduction to the 
History and Controversies of Clinical Trials in Diabetic Neuropathy. International 
Review of Neurobiology. N. A. Calcutt and P. Fernyhough, Academic Press. 127: 3-
8  
[42] Apfel SC, Asbury AK, Bril V, et al. (2001) Positive neuropathic sensory 
symptoms as endpoints in diabetic neuropathy trials. Journal of the Neurological 
Sciences 189: 3-5 
[43] Singleton JR, Marcus RL, Jackson JE, M KL, Graham TE, Smith AG (2014) 
Exercise increases cutaneous nerve density in diabetic patients without neuropathy. 
Ann Clin Transl Neurol 1: 844-849 
[44] Themistocleous AC, Ramirez JD, Serra J, Bennett DLH (2014) The clinical 
approach to small fibre neuropathy and painful channelopathy. Practical Neurology 
[45] Vas PR, Sharma S, Rayman G (2015) Distal Sensorimotor Neuropathy: 
Improvements in Diagnosis. Rev Diabet Stud 12: 29-47 
67 
 
[46] Haanpaa M, Attal N, Backonja M, et al. (2011) NeuPSIG guidelines on 
neuropathic pain assessment. Pain 152: 14-27 
[47] Lauria G, Hsieh ST, Johansson O, et al. (2010) European Federation of 
Neurological Societies/Peripheral Nerve Society Guideline on the use of skin biopsy 
in the diagnosis of small fiber neuropathy. Report of a joint task force of the 
European Fe-deration of Neurological Societies and the Peripheral Nerve Society. 
European Journal of Neurology 17: 903-e949 
[48] Lauria G, Bakkers M, Schmitz C, et al. (2010) Intraepidermal nerve fiber 
density at the distal leg: a worldwide normative reference study. J Peripher Nerv Syst 
15: 202-207 
[49] Shy ME, Frohman EM, So YT, et al. (2003) Quantitative sensory testing: 
Report of the Therapeutics and Technology Assessment Subcommittee of the 
American Academy of Neurology. Neurology 60: 898-904 
[50] Quattrini C, Tavakoli M, Jeziorska M, et al. (2007) Surrogate markers of 
small fiber damage in human diabetic neuropathy. Diabetes 56: 2148-2154 
[51] Cruccu G, Sommer C, Anand P, et al. (2010) EFNS guidelines on 
neuropathic pain assessment: revised 2009. Eur J Neurol 17: 1010-1018 
[52] Malik RA, Veves A, Walker D, et al. (2001) Sural nerve fibre pathology in 
diabetic patients with mild neuropathy: relationship to pain, quantitative sensory 
testing and peripheral nerve electrophysiology. Acta Neuropathol 101: 367-374 
[53] Malik RA, Kallinikos P, Abbott CA, et al. (2003) Corneal confocal 
microscopy: a non-invasive surrogate of nerve fibre damage and repair in diabetic 
patients. Diabetologia 46: 683-688 
[54] Pritchard N, Edwards K, Vagenas D, et al. (2010) Corneal sensitivity as an 
ophthalmic marker of diabetic neuropathy. Optom Vis Sci 87: 1003-1008 
[55] Petropoulos IN, Manzoor T, Morgan P, et al. (2013) Repeatability of in vivo 
corneal confocal microscopy to quantify corneal nerve morphology. Cornea 32: e83-
89 
[56] Chen X, Graham J, Dabbah MA, et al. (2015) Small nerve fiber 
quantification in the diagnosis of diabetic sensorimotor polyneuropathy: comparing 
corneal confocal microscopy with intraepidermal nerve fiber density. Diabetes Care 
38: 1138-1144 
68 
 
[57] Tavakoli M, Quattrini C, Abbott C, et al. (2010) Corneal confocal 
microscopy: a novel noninvasive test to diagnose and stratify the severity of human 
diabetic neuropathy. Diabetes Care 33: 1792-1797 
[58] Tavakoli M, Ferdousi M, Petropoulos IN, et al. (2015) Normative values for 
corneal nerve morphology assessed using corneal confocal microscopy: a 
multinational normative data set. Diabetes Care 38: 838-843 
[59] Tervo T, Holopainen J, Belmonte C (2016) Confocal microscopy of corneal 
nerves—a limited but still useful technique to evaluate peripheral neuropathies. 
JAMA Ophthalmology 134: 990-991 
[60] Smith AG, Russell J, Feldman EL, et al. (2006) Lifestyle intervention for 
pre-diabetic neuropathy. Diabetes Care 29: 1294-1299 
[61] Tavakoli M, Kallinikos P, Iqbal A, et al. (2011) Corneal confocal microscopy 
detects improvement in corneal nerve morphology with an improvement in risk 
factors for diabetic neuropathy. Diabet Med 28: 1261-1267 
[62] Mehra S, Tavakoli M, Kallinikos PA, et al. (2007) Corneal confocal 
microscopy detects early nerve regeneration after pancreas transplantation in patients 
with type 1 diabetes. Diabetes Care 30: 2608-2612 
[63] Boucek P, Havrdova T, Voska L, et al. (2008) Epidermal Innervation in Type 
1 Diabetic Patients. A 25-year prospective study after simultaneous pancreas/kidney 
transplantation 31: 1611-1612 
[64] Caselli A, Rich J, Hanane T, Uccioli L, Veves A (2003) Role of C-
nociceptive fibers in the nerve axon reflex-related vasodilation in diabetes. 
Neurology 60: 297-300 
[65] Caselli A, Spallone V, Marfia GA, et al. (2006) Validation of the nerve axon 
reflex for the assessment of small nerve fibre dysfunction. J Neurol Neurosurg 
Psychiatry 77: 927-932 
[66] Walmsley D, Wiles PG (1990) Assessment of the neurogenic flare response 
as a measure of nociceptor C fibre function. J Med Eng Technol 14: 194-196 
[67] Haas LF (2005) Sir Thomas Lewis 1881–1945. Journal of Neurology, 
Neurosurgery & Psychiatry 76: 1157 
[68] Roosterman D, Goerge T, Schneider SW, Bunnett NW, Steinhoff M (2006) 
Neuronal Control of Skin Function: The Skin as a Neuroimmunoendocrine Organ. 
Physiological Reviews 86: 1309-1379 
69 
 
[69] Hagains CE, Trevino LA, He J-W, Liu H, Peng YB (2010) Contributions of 
dorsal root reflex and axonal reflex to formalin-induced inflammation. Brain 
research 1359: 90-97 
[70] Krause JE, Takeda Y, Hershey AD (1992) Structure, functions, and 
mechanisms of substance P receptor action. Journal of investigative dermatology 98: 
2S-7S 
[71] Van Rossum D, Hanisch U-K, Quirion R (1997) Neuroanatomical 
Localization, Pharmacological Characterization and Functions of CGRP, Related 
Peptides and Their Receptors. Neuroscience & Biobehavioral Reviews 21: 649-678 
[72] Brain S, Williams T, Tippins J, Morris H, MacIntyre I (1985) Calcitonin 
gene-related peptide is a potent vasodilator. Nature 3-9;313(5997):54-6. 
[73] Krishnan ST, Rayman G (2004) The LDIflare A novel test of C-fiber 
function demonstrates early neuropathy in type 2 diabetes. Diabetes Care 27: 2930-
2935 
[74] Krishnan ST, Quattrini C, Jeziorska M, Malik RA, Rayman G (2009) 
Abnormal LDIflare but normal quantitative sensory testing and dermal nerve fiber 
density in patients with painful diabetic neuropathy. Diabetes Care 32: 451-455 
[75] Green AQ, Krishnan S, Finucane FM, Rayman G (2010) Altered C-fiber 
function as an indicator of early peripheral neuropathy in individuals with impaired 
glucose tolerance. Diabetes Care 33: 174-176 
[76] Boulton AJ, Malik RA (2010) Neuropathy of impaired glucose tolerance and 
its measurement. Diabetes Care 33: 207-209 
[77] Said G (2007) Diabetic neuropathy-a review. Nat Clin Pract Neuro 3: 331-
340 
[78] Vas PR, Rayman G (2013) The rate of decline in small fibre function 
assessed using axon reflex-mediated neurogenic vasodilatation and the importance of 
age related centile values to improve the detection of clinical neuropathy. PLoS ONE 
8 (7): e69920. doi:10.1371/journal.pone.0069920 
[79] O'Connor PJ (1990) Normative data: their definition, interpretation, and 
importance for primary care physicians. Fam Med 22: 307-311 
[80] Perkins BA, Grewal J, Ng E, Ngo M, Bril V (2006) Validation of a novel 
point-of-care nerve conduction device for the detection of diabetic sensorimotor 
polyneuropathy. Diabetes Care 29: 2023-2027 
70 
 
[81] Lee JA, Halpern EM, Lovblom LE, Yeung E, Bril V, Perkins BA (2014) 
Reliability and validity of a point-of-care sural nerve conduction device for 
identification of diabetic neuropathy. PLoS ONE 9(1):e86515. doi: 
10.1371/journal.pone.0086515  
[82] Sharma S, Vas PR, Rayman G (2015) Assessment of diabetic neuropathy 
using a point-of-care nerve conduction device shows significant associations with the 
LDIFLARE method and clinical neuropathy scoring. J Diabetes Sci Technol 9: 123-
131 
[83] Han Y, Smith MT (2013) Pathobiology of cancer chemotherapy-induced 
peripheral neuropathy (CIPN). Front Pharmacol 4: 156 
[84] Peltier AC, Russell JW (2002) Recent advances in drug-induced 
neuropathies. Curr Opin Neurol 15: 633-638 
[85] Boyette-Davis J, Xin W, Zhang H, Dougherty PM (2011) Intraepidermal 
nerve fiber loss corresponds to the development of taxol-induced hyperalgesia and 
can be prevented by treatment with minocycline. Pain 152: 308-313 
[86] Sharma S, Venkitaraman R, Vas PR, Rayman G (2015) Assessment of 
chemotherapy-induced peripheral neuropathy using the LDIFLARE technique: a 
novel technique to detect neural small fiber dysfunction. Brain Behaviour 5(7): 
e00354. doi:  10.1002/brb3.354 
[87] Drory VE, Groozman GB, Rubinstein A, Korczyn AD (1999) 
Hypertriglyceridemia may cause a subclinical peripheral neuropathy. Electromyogr 
Clin Neurophysiol 39: 39-41 
[88] McManis PG, Windebank AJ, Kiziltan M (1994) Neuropathy associated with 
hyperlipidemia. Neurology 44: 2185-2186 
[89] Kassem HS, Azar ST, Zantout MS, Sawaya RA (2005) Hypertriglyceridemia 
and peripheral neuropathy in neurologically asymptomatic patients. Neuro 
Endocrinol Lett 26: 775-779 
[90] Rajabally YA, Shah RS (2011) Dyslipidaemia in chronic acquired distal 
axonal polyneuropathy. J Neurol 258: 1431-1436 
[91] Hughes RA, Umapathi T, Gray IA, et al. (2004) A controlled investigation of 
the cause of chronic idiopathic axonal polyneuropathy. Brain 127: 1723-1730 
[92] Vas PR, Sharma S, Rayman G (2015) LDIflare small fiber function in normal 
glucose tolerant subjects with and without hypertriglyceridemia. Muscle Nerve 52: 
113-119 
71 
 
[93] Vas PR, Green AQ, Rayman G (2012) Small fibre dysfunction, 
microvascular complications and glycaemic control in type 1 diabetes: a case-control 
study. Diabetologia 55: 795-800 
[94] ENSPDR (2011) English National Screening Programme for Diabetic 
Retinopathy. 
[95] Zoungas S, Arima H, Gerstein HC, et al. (2017) Effects of intensive glucose 
control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis 
of individual participant data from randomised controlled trials. The Lancet Diabetes 
& Endocrinology 5(6):431-437. doi: 10.1016/S2213-8587(17)30104-3 
[96] Lagerburg V, Bakkers M, Bouwhuis A, et al. (2015) Contact heat evoked 
potentials: normal values and use in small-fiber neuropathy. Muscle Nerve 51: 743-
749 
[97] Truini A, Galeotti F, Romaniello A, Virtuoso M, Iannetti G, Cruccu G (2005) 
Laser-evoked potentials: normative values. Clinical Neurophysiology 116: 821-826 
[98] Yarnitsky D, Sprecher E (1994) Thermal testing: normative data and 
repeatability for various test algorithms. Journal of the Neurological Sciences 125: 
39-45 
[99] Wu T, Ahmed A, Bril V, et al. (2012) Variables associated with corneal 
confocal microscopy parameters in healthy volunteers: implications for diabetic 
neuropathy screening. Diabet Med 29: e297-303 
[100] Truini A, Galeotti F, Romaniello A, Virtuoso M, Iannetti GD, Cruccu G 
(2005) Laser-evoked potentials: normative values. Clinical Neurophysiology 116: 
821-826 
[101] Vas PR, Sharma S, Rayman G (2014) Comment on Breiner et al. Does the 
prevailing hypothesis that small-fiber dysfunction precedes large-fiber dysfunction 
apply to type 1 diabetic patients? Diabetes care 2014;37:1418-1424. Diabetes Care 
37: e240-241 
[102] Nabavi Nouri M, Ahmed A, Bril V, et al. (2012) Diabetic neuropathy and 
axon reflex-mediated neurogenic vasodilatation in type 1 diabetes. PLoS ONE 7(4): 
e34807. doi: 10.1371/journal.pone.0034807 
[103] England JD, Gronseth GS, Franklin G, et al. (2005) Distal symmetric 
polyneuropathy: a definition for clinical research: report of the American Academy 
of Neurology, the American Association of Electrodiagnostic Medicine, and the 
72 
 
American Academy of Physical Medicine and Rehabilitation. Neurology 64: 199-
207 
[104] Ebadi H, Perkins BA, Katzberg HD, Lovblom LE, Bril V (2012) Evaluation 
of proxy tests for SFSN: evidence for mixed small and large fiber dysfunction. PLoS 
ONE 7(8): e42208. doi: 10.1371/journal.pone.0042208 
[105] Abraham A, Alabdali M, Alsulaiman A, et al. (2016) Laser Doppler Flare 
Imaging and Quantitative Thermal Thresholds Testing Performance in Small and 
Mixed Fiber Neuropathies. PLoS ONE 11 (11): e0165731 
doi: 10.1371/journal.pone.0165731 
[106] Hinder LM, Figueroa-Romero C, Pacut C, et al. (2014) Long-chain acyl 
coenzyme A synthetase 1 overexpression in primary cultured Schwann cells prevents 
long chain fatty acid-induced oxidative stress and mitochondrial dysfunction. 
Antioxid Redox Signal 21: 588-600 
[107] Di Paolo G, Przedborski S (2013) When Schwann Cells Conspire with 
Mitochondria, Neighboring Axons Are under Attack by Glia-Derived Neurotoxic 
Lipids. Neuron 77: 801-803 
[108] Viader A, Sasaki Y, Kim S, et al. (2013) Aberrant Schwann Cell Lipid 
Metabolism Linked to Mitochondrial Deficits Leads to Axon Degeneration and 
Neuropathy. Neuron 77: 886-898 
[109] Callaghan BC, Cheng HT, Stables CL, Smith AL, Feldman EL (2012) 
Diabetic neuropathy: clinical manifestations and current treatments. Lancet Neurol 
11: 521-534 
[110] Vincent AM, Edwards JL, McLean LL, et al. (2010) Mitochondrial 
biogenesis and fission in axons in cell culture and animal models of diabetic 
neuropathy. Acta neuropathologica 120: 477-489 
[111] Feldman EL, Nave K-A, Jensen TS, Bennett DL (2017) New Horizons in 
Diabetic Neuropathy: Mechanisms, Bioenergetics, and Pain. Neuron 93: 1296-1313 
[112] Tesfaye S, Stevens LK, Stephenson JM, et al. (1996) Prevalence of diabetic 
peripheral neuropathy and its relation to glycaemic control and potential risk factors: 
the EURODIAB IDDM Complications Study. Diabetologia 39: 1377-1384 
[113] Gubitosi-Klug RA (2014) The diabetes control and complications 
trial/epidemiology of diabetes interventions and complications study at 30 years: 
summary and future directions. Diabetes Care 37: 44-49 
73 
 
[114] I. M. Stratton, R. R. Holman, Boulton AJM (2004) Risk factors for 
neuropathy in UKPDS. Diabetologia  47  Suppl  1: A47 
[115] Lee S-S, Han H-S, Kim H (2014) Peripheral Nerve Abnormalities in Patients 
with Newly Diagnosed Type I and II Diabetes Mellitus. Korean J Clin Neurophysiol 
16: 8-14 
[116] Rajabally YA (2011) Neuropathy and impaired glucose tolerance: an updated 
review of the evidence. Acta Neurol Scand 124: 1-8 
[117] Singleton JR, Smith AG, Russell JW, Feldman EL (2003) Microvascular 
Complications of Impaired Glucose Tolerance. Diabetes 52: 2867-2873 
[118] Nebuchennykh M, Loseth S, Lindal S, Mellgren SI (2009) The value of skin 
biopsy with recording of intraepidermal nerve fiber density and quantitative sensory 
testing in the assessment of small fiber involvement in patients with different causes 
of polyneuropathy. J Neurol 256: 1067-1075 
[119] Callaghan BC, Hur J, Feldman EL (2012) Diabetic neuropathy: one disease 
or two? Curr Opin Neurol 25: 536-541 
[120] Dyck PJ, Overland CJ, Low PA, et al. (2010) Signs and symptoms versus 
nerve conduction studies to diagnose diabetic sensorimotor polyneuropathy: Cl vs. 
NPhys trial. Muscle Nerve 42: 157-164 
[121] Ponirakis G, Fadavi H, Petropoulos IN, et al. (2015) Automated 
Quantification of Neuropad Improves Its Diagnostic Ability in Patients with Diabetic 
Neuropathy. J Diabetes Res 2015: 847854. http://dx.doi.org/10.1155/2015/847854 
[122] Gibbons CH, Freeman R, Veves A (2010) Diabetic neuropathy: a cross-
sectional study of the relationships among tests of neurophysiology. Diabetes Care 
33: 2629-2634 
[123] Petropoulos IN, Green P, Chan AW, et al. (2015) Corneal confocal 
microscopy detects neuropathy in patients with type 1 diabetes without retinopathy 
or microalbuminuria. PLoS ONE 10: e0123517 
[124] Clement DL (1976) Neurogenic influences on blood pressure and vascular 
tone from peripheral receptors during muscular contraction. Cardiology 61 suppl 1: 
65-68 
[125] Touyz RM, Schiffrin EL (2000) Signal Transduction Mechanisms Mediating 
the Physiological and Pathophysiological Actions of Angiotensin II in Vascular 
Smooth Muscle Cells. Pharmacological Reviews 52: 639-672 
74 
 
[126] Lincoln TM, Komalavilas P, Cornwell TL (1994) Pleiotropic regulation of 
vascular smooth muscle tone by cyclic GMP-dependent protein kinase. Hypertension 
23: 1141-1147 
[127] Lerman A, Zeiher AM (2005) Endothelial Function: Cardiac Events. 
Circulation 111: 363-368 
[128] Westby CM, Weil BR, Greiner JJ, Stauffer BL, DeSouza CA (2011) 
Endothelin-1 vasoconstriction and the age-related decline in endothelium-dependent 
vasodilatation in men. Clinical Science 120: 485-491 
[129] Hecker M, Dambacher T, Busse R (1992) Role of endothelium-derived 
bradykinin in the control of vascular tone. J Cardiovasc Pharmacol 20 Suppl 9: S55-
61 
[130] Leach RM, Hill HS, Snetkov VA, Ward J (2002) Hypoxia, energy state and 
pulmonary vasomotor tone. Respiratory physiology & neurobiology 132: 55-67 
[131] Caselli A, Spallone V, Marfia G, et al. (2006) Validation of the nerve axon 
reflex for the assessment of small nerve fibre dysfunction. Journal of Neurology, 
Neurosurgery & Psychiatry 77: 927 
[132] Rayman G, Williams SA, Spencer PD, Smaje LH, Wise PH, Tooke JE (1986) 
Impaired microvascular hyperaemic response to minor skin trauma in type I diabetes. 
Br Med J (Clin Res Ed) 292: 1295-1298 
[133] Green AQ, Krishnan ST, Rayman G (2009) C-fiber function assessed by the 
laser doppler imager flare technique and acetylcholine iontophoresis. Muscle Nerve 
40: 985-991 
[134] Caselli A, Uccioli L, Khaodhiar L, Veves A (2003) Local anesthesia reduces 
the maximal skin vasodilation during iontophoresis of sodium nitroprusside and 
heating. Microvasc Res 66: 134-139 
[135] Emanuel AL, Nieuwenhoff MD, Klaassen ES, et al. (2017) Relationships 
Between Type 2 Diabetes, Neuropathy, and Microvascular Dysfunction: Evidence 
From Patients With Cryptogenic Axonal Polyneuropathy. Diabetes Care 40: 583-590 
[136] Vas PR, Rayman G (2012) Validation of the modified LDIFLARE technique: 
A simple and quick method to assess C-fiber function. Muscle Nerve 47(3):351-6.  
[137] Krishnan ST, Quattrini C, Jeziorska M, Malik RA, Rayman G (2009) 
Abnormal LDIflare but normal quantitative sensory testing and dermal nerve fiber 
density in patients with painful diabetic neuropathy. Diabetes Care 32: 451-455 
75 
 
[138] Sivaskandarajah GA, Halpern EM, Lovblom LE, et al. (2013) Structure-
function relationship between corneal nerves and conventional small-fiber tests in 
type 1 diabetes. Diabetes Care 36: 2748-2755 
[139] Illigens BM, Siepmann T, Roofeh J, Gibbons CH (2013) Laser Doppler 
imaging in the detection of peripheral neuropathy. Auton Neurosci 177: 286-290 
[140] Kluding PM, Pasnoor M, Singh R, et al. (2012) The effect of exercise on 
neuropathic symptoms, nerve function, and cutaneous innervation in people with 
diabetic peripheral neuropathy. Journal of Diabetes and Its Complications 26: 424-
429 
[141] Azmi S, Ferdousi M, Petropoulos IN, et al. (2015) Corneal confocal 
microscopy shows an improvement in small-fiber neuropathy in subjects with type 1 
diabetes on continuous subcutaneous insulin infusion compared with multiple daily 
injection. Diabetes Care 38: e3-4 
[142] Vas PRJ, Sharma S, Rayman G (2014) Comment on Breiner et al. Does the 
Prevailing Hypothesis That Small-Fiber Dysfunction Precedes Large-Fiber 
Dysfunction Apply to Type 1 Diabetic Patients? Diabetes Care 2014;37:1418–1424. 
Diabetes Care 37: e240-e241 
[143] Vas PRJ, Alberti KG, Edmonds ME (2017) Prediabetes: moving away from a 
glucocentric definition. Lancet Diabetes Endocrinol 5: 848-849. doi 10.1016/S2213-
8587(17)30234-6 
 
 
 
 
 
A 
Appendix A: Statements of contribution signed by all co-authors 
 







 B 
Appendix B: Publications included in the thesis 
 
